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ABSTRACT: 
 
Selective serotonin reuptake inhibitors (SSRIs) are a new class of antidepressants 
used mainly for the treatment of depression and other forms of related disorders. 
There are a number of side effects associated with these drugs which include loss of 
weight, sexual dysfunction, nervousness and nausea. A fast and reliable detection 
method such as biosensing for the determination of the SSRIs metabolic profile is 
therefore essential for the appropriate dosing of these drugs. Biosensors for the 
determination of the SSRIs biotransformation were prepared with cytochrome P450-
2D6 (CYP2D6) isoenzyme and poly (anilinonapthalene sulfonic acid) (PANSA) film 
electrochemically deposited on gold. The biotransformation of the SSRIs was studied 
by the use of Cyclic voltammetry (CV), Square wave voltammetry (SWV) and 
Differential voltammetry (DPV) under aerobic conditions The surface concentration 
of the adsorbed electroactive film was determined and estimated to be 1.0257 x 10-6 
mol cm-2 and the charge transfer coefficient was estimated to be 3.8225 x 10 2 cm s-
1.The biosensor response time, sensitivity, detection limit and dynamic linear range 
were determined for sertraline, fluoxetine, fluvoxamine, citalopram, zimelidine and 
paroxetine. Analysis of the Michaelis-Menten region of the sensor response curves for 
the SSRs gave apparent Michaelis-Menten constants which were higher than the peak 
plasma concentration (Cmax) value of 0.55 μM, thereby making the sensor systems 
suitable for the determination of the respective analytes in serum. 
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CHAPTER 
ONE 
 
Background: 
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1.1 INTRODUCTION: 
About 121 million people worldwide have a common mental disorder known as 
depression. Depression is believed to be as a result of a deficit in the availability of 
serotonin and noradrenalin (Pedrazza et al, 2007). It is assumed that 50% of all suicide 
attempts in the Western World are due to depression while 25% of severe depressed 
patients attempt at least one suicide. This illness affects both the economic as well as the 
social functioning (Pedrazza et al, 2007) of the individual patient thus leading to suicidal 
behaviour. According to research done by the World Health Organization, this disorder 
will be the second major contributor to disease by the year 2020, calculated for both 
sexes and for both ages. Between the years 1960 to 1980, this condition was treated with 
tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (Wilke et al, 2005; 
Heimke et al, 2000; Malfara et al, 2007).  
However it was later discovered that the side effects as well as severe drug-drug 
interaction of these compounds in conjunction with the development of the study of the 
central nervous system, has led to the production and development of several new 
antidepressants (Wilke et al, 2005; Heimke et al, 2000, Murrin et al, 2007). Today 
depression is treated by a new class of antidepressants known as Selective Serotonin 
Reuptake Inhibitors (SSRIs), of which Fluoxetine is the most commonly known and used 
(Heimke et al, 2000). This group of drugs also includes, Fluvoxamine, Citalpram, 
Sertraline, Zimelidine and Paroxetine. Studies have shown that depression is linked to a 
lack of stimulation of the recipient neuron at a synapse. Therefore, SSRIs function in a 
manner whereby they block the re-uptake of serotonin from the synaptic junctions in the 
brain, enhancing central serotonergic function. This way serotonin would have enough 
time and the chance to be recognized again and again by receptors of the recipient cell, 
 2
 
 
 
 
which are then stimulated. Since SSRIs have a high selectivity for serotonin reuptake, 
they therefore do not cause the unwanted blockage of peripheral and central adrenergic, 
cholinergic and histaminergic receptors that is characteristic of TCAs and monoamino 
oxidase inhibitors (Bistrolas et al, 2005; Heimke et al, 2000; Schreiber et al, 2006). 
SSRIs became popular instantly and this was attributed to the advantages over the TCAs 
and monoamine oxidase inhibitors in terms of safety, tolerability and ease of dosing. 
Since their introduction in the mid-eighties, over 35 million patients have been treated 
with SSRIs. Later it was discovered that certain limitations, associated with a failure in 
response in many of the severely affected patients resulted in many of them to end 
treatment. The ending is mainly due to the side effects such as gastrointestinal 
complaints; nervousness and agitation, sexual dysfunction and weight gain mainly to 
long-term users. These factors outlined a problem with the dosing of these drugs among 
diagnosed patients.   
The aim of this work is the development of a bio-analytical device, which is suitable for 
the appropriate dosing of clinically, diagnosed patients by the measurement of SSRIs. 
This device is known as a biosensor which when constructed is tailored to match the 
individual demands of the specified analyte (D ‘Orazio et al, 2003).   A review of the 
current literature suggests that an isoform of the heme-thiolate cytochrome P450 proteins 
is indicated in the metabolism of these drugs. CYP2D6, isoform also known as 
debrisoquine hydroxylase is thought to be responsible for the biotransformation of 
fluoxetine to nor-fluoxetine and it is therefore believed that it will behave in the same 
manner with the other SSRIs. On the other hand this enzyme is inhibited by high 
 3
 
 
 
 
concentrations of fluoxetine and is therefore incapable of normal functions (Hermeryck et 
al, 2003). 
Currently high performance liquid chromatography and gas chromatography methods are 
used for quantifying the levels of fluoxetine and its metabolites in blood and plasma. 
Although these methods are well established and accurate they require substantial sample 
preparation, which then led to the construction of biosensors as they have reduced sample 
preparation time and allow for point of care analyses. In this project I will investigate the 
electrochemical interaction between CYP2D6 and fluoxetine as well as other SSRIs 
mediated by poly (8-anilino-1-napthalene sulphonic acid). I will also investigate the role 
of inhibitors of CYP2D6 bioactivity that may be present.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2  RATIONALE AND MOTIVATION: 
 4
 
 
 
 
The study being proposed is a synergy of electrochemical and molecular electronic 
principles in the development of novel micro- or nano-structured or nano-meter scale 
electrochemical sensor devices for biomedical, environmental and biomolecular analysis. 
The material of interest in this study is the polymer PANSA synthesized from a 
derivative of naphthalene sulphonic acid, aniline naphthalene sulfonic acid (ANSA). The 
specific application of the proposed sensor system for the elucidation of the metabolism 
of SSRI drugs is being proposed. The advent of SSRI drugs increased the 
pharmacological options for the treatment of depression by enhancing serotonergic 
transmission and inducing down-regulation of postsynaptic receptors. These third 
generation antidepressants provide effective antidepressant activity without the sedating, 
anticholinergic, or cardiotoxic reactions observed with tricyclic antidepressants (Gram et 
al, 1994; Hermeryck et al, 2003; Pedrazza et al, 2007). Fluoxetine, an SSRI drug is 
presently the most prescribed antidepressant mainly due to its proven efficacy, ease of 
administration, generally benign side-effect profile (involving mainly the gastrointestinal 
system) and remarkable safety in over-dose (Schreiber et al, 2006; Malfara et al, 2007). 
However, the fate of fluoxetine after administration still remains controversial (Wedlund 
et al, 2004). Norfluoxetine the metabolite of fluoxetine, is also as potent as the parent 
compound. It has an elimination half-life of about 330 hours, so that pharmacologically 
active compounds remain present in the body for up to 7 days following a fluoxetine dose 
(Hermeryck et al, 2003). 
In this study I will combine the bioelectronics and bioelectrochemistry of redox enzyme 
isoforms with the electron mediating ability and conductivity of electroactive 
nanopolymers for electrochemical study and modelling of SSRIs metabolism.  The 
 5
 
 
 
 
feasibility of the study is borne out by the fact that recent studies (Wedlund et al, 2004; 
Koyama et al, 1997; Vickers et al, 2001; Degtyarenko et al, 1995; Iwuoha et al, 1997) 
suggest that cytochrome P450-2D6 may be the major enzyme catalysing the N-
demethylation of fluoxetine to R- and S-norfluoxetine. Incidentally, human CYP2D6 is 
evolutionarily of the Type II P450 (microsomal) class (Shumyantseva et al, 2005) which 
normally consists of an NADPH: P450 reductase (FAD- and FMN-containing 
flavoprotein) and the P450 enzyme. The design of the resultant device is to eliminate the 
need for CYP2D6 physiological or artificial co-factors in the biocatalysis of SSRIs 
metabolism, by elegantly combining the use of genetically engineered CYP2D6 and 
cathodic polarization of the enzyme immobilized in the nanopolymer as the source of the 
requisite electrons.  
Clinically it is important to determine the CYP2D6 profile of patients before 
administering fluoxetine or other SSRIs drugs metabolised by CYP2D6. The SSRIs drugs 
metabolising status of patients would be evaluated by the use of sensor systems that 
would consist of poly (8-anilino-1- naphthalene sulphonic acid) PANSA modified 
electrodes and samples of SSRIs. 
 
 
 
 
 
 
 
 
1.3 AIM OF THE STUDY: 
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The project will investigate the electrochemical interactions between CYP2D6 and 
SSRIs. This interaction will be mediated by PANSA on a gold electrode. The result of 
this will then establish an electrochemical method for studying the biotransformation of 
SSRIs by amperometric transduction. 
 
The objectives of the study are: 
1) To prepare biorecognition electrodes containing CYP2D6 isoforms in poly (8-
anilino-1-naphthalenesulphonic acid.  
2) To demonstrate electrochemical responses and reactivities of the sensors. 
3) To generate Dose response curves for SSRIs 
      4)        To model the amperometric and kinetic responses of the nanosensor systems 
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2.1 BIOSENSORS: 
Biosensors are increasingly becoming practical and useful, if not essential tools in 
medicine, food quality control, environmental monitoring and research. In their design 
they can be tailored to match individual analytical demand for almost any target molecule 
or compound that interacts specifically with a biological system. Biosensors are devices 
that are used to detect analytes as a result of their interaction with a bioactive substance, 
which is usually attached to an electrode. Generally, these devices are composed of a 
bioactive substance as well as a physical transducer (Brennan et al, 1996; D ‘Orazio et 
al, 2003) as illustrated in Figure 2.1.  
 
 
SIGNAL
ANALYTE RECEPTOR TRANSDUCER ELECTRONICS 
 
Fig 2.1: Components of a biosensor 
 
The bioactive substance is immobilized in close proximity to a transducer that relays the 
interaction of the analyte and the bioactive substance into a measurable response which is 
most often an electronic signal (Brennan et al, 1996; D ‘Orazio et al, 2003). The 
bioactive substance also known as a chemically selective layer or sometimes as a receptor 
is responsible for the determination of the sensitivity of the sensor. Each receptor has its 
own specific detector, which is able to produce a particular expected signal. Table 2.1 
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(Conn et al, 1987) illustrates the most commonly used receptors and detectors in 
biosensor construction.  
Table 2.1: Bioactive components and transducers used in biosensor design
BIOACTIVE COMPONENT TRANSDUCER 
Organisms Potentiometric 
Tissues slices Amperometric 
Whole microbial Cells Conductometric 
Organelles Impedimetric 
Membranes Optical 
Enzymes Calorimetric 
Enzyme components Acoustic 
Receptors Mechanical 
Antibodies Molecular electronic 
Nucleic acid  
Organic molecules  
 
Biosensors can be divided into three generations depending on their level of integration. 
The first generation comprises of a biocatalyst that is either bound or entrapped in a 
membrane. The second generation of biosensors involves the adsorption of the biological 
components to the transducer surface thereby eliminating semi-permeable membranes. In 
the third generation, there is a direct binding of the biocatalyst to an electronic device that 
transduces and then amplifies the signal. Conducting polymer based biosensors are 
placed in this category (Chaubey et al, 2002). A successful biosensor possesses some 
beneficial features such as; the bioactive substance should be highly specific for the 
purpose of the analyses. The reaction, which takes place, should be independent of 
physical parameters such as stirring, pH and temperature as this would allow minimal 
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pre-treatment of samples prior to analysis. The obtained response after analysis should be 
accurate, precise, reproducible and linear over the useful analytical range. The response 
should also be free from electrical noise. Most importantly, the complete biosensor 
should be cheap, small, portable and capable of being operated by semi-skilled operators 
(Ryan-Byrne et al, 1997). Some potential applications of biosensors are in clinical 
diagnosis, agricultural and horticultural analysis, pollution, water and microbial 
contamination analysis. 
2.1.1 Receptors: 
In biosensors, receptors are compounds or materials that give biosensors their selectivity 
characteristics. In most cases these receptors undergo reactions with their respective 
analytes which is denoted by an end signal. Various receptors have been employed in 
sensor construction. In this section we shall give an indication of a few commonly used 
receptors. 
Plant tissues as well as some sections of mammals have been employed in the 
construction of biosensors resulting in sensor systems with greater selectivity’s when 
compared to those constructed with bacterial cells. This is due to the fact that plants and 
animals are not metabolically versatile. Each type of tissue slice functions the best when 
the appropriate analyte is present. Different types of tissues and their corresponding 
analytes are shown in Table 2.2 obtained from (D’Orazio et al, 2003). Whole microbial 
cells are also widely utilized in the study of biosensors and are often used when the 
desired enzyme is either unstable or difficult to purify. A slight disadvantage  associated 
with these biosensors in that they have a slow response time and they require a need for 
frequent calibration. Whole cell biosensors have been constructed to analyse ammonia, 
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antibiotics, enzyme activities, sugars, peptides, vitamins, nitrates, alcohols, biological 
oxygen demand and organic acids.  
Enzymes are the most widely used biological components and research has shown that 
most enzymes have been successfully used in the construction of biosensor These 
components are unique since they are a combination of selectivity and sensitivity and 
they allow for a wide selection of transducers to be used (Conn et al, 1987). The signals 
of enzyme sensors are strongly influenced towards their application by inhibition, 
temperature and pH dependence (D’Orazio et al, 2003). Our work involves the 
construction of a biosensor with the aid of the enzyme cytochrome P450 2D6 
immobilized onto a polymer film. 
Table 2.2: Tissues used to date and their respective analytes 
TISSUE  ANALYTE 
Mouse intestinal mucosa Adenosine 
Cucumber leaf Cysteine 
Banana pulp Dopamine 
Yellow squash Glutamate 
Bovine liver H2O2
Corn kernel Pyruvate 
Sugar beet Tyrosine 
Jack bean meal  
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2.1.2 Transducers: 
The role of a transducer in biosensor construction is to relay the interaction of the 
biological active compound and the analyte into a measurable response which in most 
cases is an electronic signal (Brennan et al, 1996). A suitable transducing system can be 
adapted in sensor construction depending on the nature of the biochemical interaction of 
the bioactive substance with the species of interest.  
Physical transducers vary from thermal, piezometric, spectroscopic, surface wave 
technology and electrochemical. Electrochemical transduction is the most common where 
amperometric and potentiometric transduction are the commonly utilized types in sensor 
studies. These methods are unique in such a manner that during the bio-interaction 
process, electrons are either consumed or generated producing an electrical signal, which 
is then detected by an electrochemical detector. An amperometric biosensor is driven by 
an external constant potential, during which an electrochemical reaction takes place, and 
the resultant current is measured (Malhotra et al, 2006; Chaubey et al, 2002; Tess et al, 
1999). Potentiometric biosensors are based on ion-selective or gas sensing electrodes 
where a movement of ions into a membrane at a zero current allows for the monitoring of 
the cell potential (Malhotra et al, 2006; Chaubey et al, 2002). A Piezometric sensor is 
another type which is based on the movement of materials into or out of a surface layer 
where the change in mass is monitored (Rojas-Malgarejo et al, 2003; D ‘Orazio et al, 
2003). Another type is thermometric biosensors which are based on the measurement of 
changes in temperature of the enzymatic reaction by the simple measurement of variation 
in resistance (Conn et al, 1987). 
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Biosensors that employ enzymes as their receptors require that the enzyme be 
immobilized onto a membrane and onto an appropriate electrode. Depending on the type 
of electrode to be used, example glassy carbon, diamond, pyrolytic graphite, there are 
either two or only one membrane separating the enzyme and the medium. 
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2.2 ENZYMES: 
Enzymes are protein catalysts, which are responsible for speeding up the rates of 
chemical reactions without being used up in the chemical processes. They lower the 
activation energy needed to convert a substrate into a product by temporarily binding to 
the substrate. The activation energy of a reaction is the energy required to form the 
transition state, so it is lowered when the enzyme stabilizes the transition state. The 
macromolecular components of almost all enzymes are composed of protein except for a 
class of Ribonucleic Acid modifying catalyst known as Ribozymes (Conn et al, 1987).  
Ribozymes are molecules of ribonucleic acid, which are responsible for catalysing 
reactions on the phosphodiester bond of other Ribonucleic acids. There are about 40,000 
different enzymes in human cells, in which each of them controls a specific reaction. The 
rates of reactions are increased by a factor between 106 to 1012 times which therefore 
allows the chemical reactions, which make life possible to take place at normal 
temperature (Conn et al, 1987). 
 
2.2.1  Mechanism of enzyme action: 
The basic mechanism by which enzymes speed up the rate of chemical reactions begins 
with the binding of the substrate or substrates to the active site of an enzyme to form an 
enzyme-substrate complex as illustrated in Scheme 2.1. 
 
E    +    S   ↔   ES   ↔   E    +    P 
 
Scheme 2.1 Mechanism of enzyme action 
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The active site of an enzyme (E) is the specific region of the enzyme where the substrate 
(S) attaches, therefore it is said to have a geometric shape that is complementary to the 
geometric shape of the substrate. This enzyme-substrate (ES) interaction causes changes 
in the distribution of electrons in the chemical bonds of the substrate thereby stimulating 
the reactions that lead to the formation of products (P). Once the products are produced, 
the enzyme is released and regenerated for another reaction. The mechanism of enzyme 
action can be further explained using the Lock and Key Theory and the Induced Fit 
Model (McMurry et al, 1998). 
 
 2.2.1.1   Lock and Key Theory: 
This theory is based on the concept that a substrate molecule fits into the active site of an 
enzyme like a key fitting into a lock. This means that only those specifically sized 
substrates will be able to fit into a particular shaped enzyme. When this interaction 
occurs, the shape of the enzyme changes slightly, changing the substrate and the active 
site, making it more likely to change into the product. If however the substrate does not 
fit correctly to the active site then no reaction occurs (McMurry et al, 1998). 
 
2.2.1.2   Induced Fit Theory: 
The induced fit model is as a result of the assumption that the substrate plays a role in 
determining the final shape of the enzyme. The model also suggests that the initial 
enzyme-substrate interaction results in conformational changes in the enzyme, which 
causes the binding to strengthen. Transition-state complexes and reaction products are 
generated after binding by one or more mechanisms of catalysis.  
There are four mechanisms of catalysis namely:  
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(a) Catalysis by Bond Strain is a catalysis where strained substrate bonds are produced as    
a result of the induced structural rearrangement which takes place when the enzyme 
      and substrate bind.  
(b) Catalysis by Proximity and Orientation is when the reactive group in an enzyme- 
      substrate interaction are orientated and brought into close proximity with one another. 
(c)  Catalysis Involving Proton Donors and Acceptors. 
(d)  Covalent Catalysis occurs when the substrate is orientated to an active site on the 
       enzyme such a manner that a covalent intermediate is generated between the enzyme  
       and the substrate (Conn et al, 1987). 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2 FACTORS AFFECTING THE RATE OF ENZYME  
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                                          REACTION: 
2.2.2.1 Temperature: 
Enzymes function at an optimum temperature and each enzyme functions best at its own 
particular temperature.  As the temperature rises the rate increases due to the fact that the 
enzyme and the substrate molecules both have more kinetic energy and hence will collide 
more often and will have sufficient energy to overcome the activation energy. The 
increase in rate with temperature can be quantified as a Q10, which is the relative 
increase for a 100C rise in temperature. Beyond the optimum temperature, the enzymes 
become denatured and ineffective. The thermal energy breaks the hydrogen bonds 
holding the secondary and tertiary structure of the enzymes, so that the enzyme loses 
shape and becomes a random coil. The substrate will then be unable to bind to it and the 
reaction is no longer catalyzed (Conn et al, 1987; Fersht et al, 1984). 
 
2.2.2.2 Enzyme concentration: 
When the concentration of the enzyme is increased, the rate of the reaction increases 
linearly due to the unavailability of enzyme molecules to catalyze the reaction. At very 
high enzyme concentration, the rate stops increasing as a result of the substrate 
concentration being rate-limiting (Conn et al, 1987; Fersht et al, 1984). 
 
2.2.2.3 pH: 
Enzymes have an optimum pH at which they function the best and for most enzymes this 
pH is from 7-8, which is the physiological pH of most cells. A few enzymes can work at 
extreme pH, such as protease enzymes in the stomach of animals which have an optimum 
pH of 1. The charge of the amino acids at the active site is affected by pH and therefore 
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the properties of the active site change causing the substrate to no longer bind to the 
enzyme (Conn et al, 1987; Fersht et al, 1984). 
 
2.2.2.4 Substrate concentration: 
As the concentration of the substrate increases, the rate also increases because more 
substrate molecules collide with the enzyme molecules, so more reactions will take place. 
At higher substrate concentrations the enzyme molecules become more saturated with the 
substrate, resulting in fewer free enzyme molecules. Therefore addition of more substrate 
towards the reaction with the enzyme does not make much difference. The rate of an 
enzyme-catalyzed reaction shows a curved dependence on substrate concentration, 
although it will increase the rate of the enzyme-substrate collisions. At infinite substrate 
concentration, the maximum rate is called Vmax and the substrate concentration that gives 
half of Vmax is called Km. Therefore an effective enzyme has a high Vmax and a low Km 
(Conn et al, 1987; Fersht et al, 1984). 
 
 
 
 
 
 
 
 
 
 
2.2.3 CLASSIFICATION OF ENZYMES: 
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Enzymes are classified on the basis of their composition. Those enzymes, which are 
composed of protein only, are known as simple enzymes as apposed to complex 
enzymes, which are composed of protein and a small organic molecule. Complex 
enzymes are also known as haloenzymes in which the protein component is known as the 
apoenzyme and the non-protein component is known as the coenzyme or a prosthetic 
group. Those enzymes that require a metal in their composition are known as 
metalloenzymes provided that after binding they still retain their metal atom under all 
reaction conditions (Conn et al, 1987). Enzymes can be classified as shown in Table 2.3: 
 
Table 2. 3: Classification of enzymes and their biochemical properties 
CLASSIFICTION BIOCHEMICAL PROPERTIES 
OXIDOREDUCTASES Remove or add Hydrogen by acting on 
chemical groupings 
TRANSFERASES They transfer functional groups between 
donor and acceptor molecules. 
HYDROLASES They hydrolyse bonds by adding water 
across it 
LYASES  Add ammonia, water or carbon across 
double bonds, or remove those elements to 
produce double bonds. 
ISOMERASES Carry out many kinds of isomerisation, L 
and D isomerisation and mutase reactions. 
 
 
 
 
2.2.4 ENZYME KINETICS: 
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Enzyme kinetics is the study of the rate at which enzymes work. It is studied as a function 
of the substrate concentration available to the enzyme. The kinetics of simple reactions 
was first characterized by the biochemists Michaelis and Menten.  
The Michaelis-Menten Equation is as follows: 
 
Vi = Vmax [S] 
{Km + [S]} 
 
This equation describes the relationship between the rate of a particular enzyme-catalysed 
reaction [Vi], the concentration of the substrate [S] and   the two constants, Vmax and Km, 
which are the maximum reaction rate and the Michaelis-Menten constant respectively. 
The above equation illustrates that the substrate concentration that produces exactly half 
of the maximum rate, the substrate concentration is equal to Km. The equation can be 
rearranged as follows: 
 
Km = [S] {[Vmax /Vi] – 1} 
 
Therefore since the substrate concentration is half that required to enhance the maximum 
rate of reaction, the observed rate, Vi, will be equal to Vmax divided by two. At this 
substrate concentration Vmax /Vi will be equal to two, with the result that [S](1) = Km. A 
graphical representation of reaction rate (Vi) versus concentration [S] produces a 
hyperbolic rate plot as shown in Figure 2.2 (Fersht et al, 1984). 
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Fig 2.2:  Illustration of Michaelis-Menten Kinetics 
 
The plot has key features denoted as points A, B, and C. It has been found that at high 
substrate concentration, the rate of reaction denoted by C is almost equal to Vmax with the 
difference being in nearby substrate concentrations, being almost negligible. If the plot is 
extrapolated to infinitely high substrate concentration, the extrapolated rate is equal to 
Vmax. On the other hand, the rate of reaction becomes independent of the concentration of 
the substrate, and the rate is said to be zero order. The substrate concentration has a very 
small difference in reaction velocity around point C, meaning that at these concentrations, 
almost all of the enzyme molecules are bound to the substrate and the rate is not 
dependent on the substrate. 
Point A and B are the lower substrate concentrations and here the velocities are lower 
which indicates that at any moment, a portion of the enzyme molecules are bound to the 
substrate. In fact, at the substrate concentration denoted by point B, exactly half of the 
enzyme molecules are in the enzyme-substrate complex at any instant and the rate is 
exactly one half of Vmax. At substrate concentrations, near point A the rate appears to be 
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directly proportional to substrate concentration, and the reaction rate is said to be first 
order. In our study, Vmax as well as Km have been calculated based on this kinetics study 
(Fersht et al, 1984). 
 
2.2.4.1 Enzyme Inhibition: 
Enzyme inhibitors are compounds that have the ability to reduce the rate of enzyme-
catalyzed reaction, by interacting with the enzyme, cofactor or the substrate. Upon 
inhibition, the enzyme is unable to bind the substrate and the catalytic ability of the 
enzyme is reduced hence Km is affected. Kcat , which is the amount of substrates 
converted to form products at a unit time, as well as the catalytic efficiency of the 
enzymatic reaction is also affected. There are two types of inhibitors namely; reversible 
and irreversible.  
Irreversible inhibitors are unable to be physically separated from the enzyme and it had 
been observed that their degree of inhibition tends to increase with time. On the other 
hand, reversible inhibitors can be separated physically from the enzyme restoring the 
enzymatic activity it had prior to inhibition. Therefore a reversible inhibition process 
occurring for a single-intermediate enzymatic reaction can be described as competitive, 
uncompetitive, non-competitive, mixed effects and allosteric inhibition (Conn et al, 1987; 
Fersht et al, 1984). 
 
2.2.4.1.1 Competitive Inhibition: 
Competitive inhibitors have a similar structure to the normal substrate molecule and they 
compete with the substrate for the active site of the enzyme, causing the reaction to be 
slower. The enzyme-bound inhibitor can either inactivate the enzyme’s ability to function 
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or it can be bind to an unfavourable position for the catalytic reaction to take place with 
potential substrate molecules. During a catalytic reaction, at a particular enzyme and 
substrate concentration, if the substrate concentration is lower than that of the inhibitor, 
then the inhibitor will favourably compete with the substrate for the enzyme binding site 
and the degree of inhibition is high. When the substrate concentration is high, this effect 
is reversed. These inhibitors increase Km for the enzyme but have no effect on Vmax, so 
the rate can approach a normal rate if the substrate concentration is increased high 
enough (Conn et al, 1987; Fersht et al, 1984). 
V = Vmax [S] 
Km (1 + 1/Ki) + [S] 
 
 
2.2.4.1.2   Non-competitive Inhibition:  
Non-competitive inhibitors are quite different in structure to the substrate molecule and 
therefore do not fit into the active site of enzymes. Inhibition occurs at other parts of  the 
enzyme changing the shape of the entire enzyme including the active site in such a 
manner that the substrates can no longer bind. The inhibitors decrease Vmax but have no 
effect on Km. The following equation clearly illustrates these findings. 
 
V = (Vmax [S])( Km + [S]) 
1 + 1/Ki
 
In this case the degree of inhibition is dependant on the concentration of the inhibitor as 
well as its affinity for the enzyme or the enzyme-substrate complex. These interactions 
are displayed in a Lineweaver-Burk Plots as illustrated in Figure 2.3.  
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Fig.2.3:  Illustration of Competitive and Non-competitive Inhibition 
 
2.2.1.3 Mixed effects inhibition: 
This method is used to describe inhibition systems which obey Michaelis-Menten 
kinetics. These systems do not show any characteristics that are any way similar to 
competitive and non-competitive inhibition. In this case both Km and Kcat are affected 
(Fersht et al, 1984).  
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2.2.5 IMMOBILIZATION OF ENZYMES: 
The phrase immobilization implies the physical attachment of an enzyme to a solid 
support over which a substrate is passed and converted to products. These enzymes are 
confined with retention of their catalytic activity and permit the re-use of the costly 
biological molecule thereby allowing a significant simplification of the analytical 
apparatus. Enzymes are by far the most commonly used biological components in 
biosensor construction. The localization of enzymes can be achieved through a variety of 
methods, which fall into four main categories (Worsfold et al, 1995) classified as follows: 
(a) Covalent binding of the enzyme to a derivatised, water insoluble matrix 
(b) Intermolecular cross-linking of enzyme molecules using multifunctional reagents 
(c) Adsorption of the enzymes onto a water-insoluble matrix 
(d) Entrapment of the enzyme inside a water-insoluble polymer lattice or semi-
permeable membrane. 
Immobilized enzymes have become increasingly popular in the past decade due to their 
reusability; hence their cost saving, greater efficiency and the ability to control their 
catalytic activity such as predictability of decay rates, potentially longer half-lives and 
more efficient multi-step reactions. There are three distinct forms in which immobilized 
enzymes can be presented: 
(a) As solid-phase immobilized enzyme reactors (packed bed and open tubular). 
These are mainly used in continuous flow techniques such as flow injection 
analysis and post-column derivatization in liquid chromatography. 
(b) When immobilized enzyme membranes are incorporated into sensors such as 
potentiometric enzyme electrodes and optical sensors. 
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(c) Solid-phase immobilized enzyme films are used in disposable, dry reagent kits 
with photometric detection. 
There are aspects of the immobilization procedure, which have to be well understood 
before the procedure can be successfully carried out. These aspects are not dependent on 
the physical form of the immobilized enzymes, whether it may be solid-phase reactor or 
membrane phase film.  
They are namely 
(a) The properties of the free enzyme 
(b) The type of support used 
(c) The methods of support activation and enzyme attachment (Worsfold et al, 1995). 
 
2.2.5.1 Properties of free enzymes: 
In nature, each enzyme irrespective of its origin or its metabolism has its own unique 
systematic name which gives the description of the type of catalysis carried out by the 
enzyme. Each enzyme possesses a four-number code, which describes other aspects of 
the enzyme. The classification scheme for enzymes was developed in 1961 by the 
International Commission on Enzymes but is was originally established in 1956 by the 
International Union of Biochemistry in consultation with IUPAC; however this scheme is 
regularly updated. The first number in the code gives an indication of the type of reaction 
that is being catalysed by the enzyme, the following two numbers indicates the subclass 
and the sub-subclass of the reaction and finally the fourth number identifies the enzyme. 
In addition to this, each enzyme has a rival name, which is commonly used. An example 
of this is the enzyme lipase as it is commonly known but also has the systematic name of 
 29
 
 
 
 
glycerol ester hydrolase with an associated code number of 3.2.1.1 (Worsfold et al, 1995). 
Table 2.4 gives a few commonly used enzymes and their respective analytes. 
 
Table 2.4: Examples of enzymes used in biosensors and analytes 
That have been analysed. 
ENZYMES ANALYTE 
β-Glucosidase Amygdalin 
Asparaginase Asparagine 
Cholesterol oxidase Chloesterol 
Chymotrypsin Esters 
Glucose oxidase Glucose 
Catalase H2O2
Lipase Lipids 
Penicillinase Penicillin G 
Trypsin Peptides 
Amylase Starch 
Invertase Sucrose 
Urease Urea 
Uricase Uric acid 
 
Comparison of enzymes is an important factor since the source of the enzyme is usually 
of great interest; however a few steps have to be taken in order to achieve this effectively. 
First and foremost is the specification of the properties of the original enzyme prior to 
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immobilization in which the working names including the systematic name along with 
the associated code number have to be well stated. The following information which is 
also of importance is; the source of the enzyme, its physical form such as being 
lyophilized, its purity which is usually given in a percentage, its method of purification, 
its catalytic activity and the details of other constituents have to be clearly stated as well. 
Therefore, if one has four different enzymes then a precise and direct comparison of the 
enzymes can be made based on the information stated on the respective enzyme 
containers. Another important enzyme parameter is catalytic activity since it has a direct 
bearing on sensitivity. 
The most widely used unit of activity is the International Unit (I.U.) which states that one 
I.U. is the amount of enzyme activity that catalyzes the transformation of one micromole 
of substrate per minute at 250C under optimal experimental conditions. The most 
recommended unit however, is the katal, which can be, defined as the amount of enzyme 
activity that catalyses the transformation of one mole of substrate per second at 250C 
under optimal experimental conditions (Worsfold et al, 1995).  
                                                                                                                                    
2.2.5.2 Enzyme Support: 
It is very difficult to predict in advance which support is the most suitable for a particular 
enzyme due to the fact that the support has a somewhat important and a critical effect on 
the stability and hence the efficiency of the immobilization of the enzymes. The support 
material must meet certain criteria for it to be efficient for immobilization and this 
includes its capability of being soluble in water, its increased capacity to bind a particular 
enzyme, its mechanical stability and finally if it is chemically inert or not. The term inert 
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solely refers to the degree of non-specific adsorption of the pH, pressure and the stability 
of temperature including hydrophilicity as well as charge transfer. The binding capacity 
of an enzyme is determined by the availability of surface area, which includes both the 
internal pore size as well as the external bead sizes of the tubular diameter. In addition to 
these, the extents of ease at which the support can be activated together with the resultant 
density of the enzyme’s binding sites are also taken into consideration. The activity of the 
immobilized enzyme is very important as it governs the enzymes reaction, therefore due 
to this, the local diffusion properties of the system as well as the bulk mass transfer 
should be closely monitored (Worsfold et al, 1995). 
Presently there is no universally recommended support material. Various materials have 
been used to compromise for each particular enzyme and experimental system. However 
the type of support materials can be classified into one of three categories, namely: 
(a) Supports which are hydrophilic biopolymers based on natural polysaccharides 
such as agarose, dextran and cellulose. 
(b) Those, which are lipophilic synthetic organic polymers such as polyacrylamide, 
polystyrene and nylon. 
(c)  Those support which are inorganic materials such as controlled pore glass and 
iron oxide. 
The chemical structure of the support must be clearly shown as defined and if there are 
any quantitative physical and chemical data relevant to the three factors stated above 
should be provided (Worsfold et al, 1995). 
 
2.2.5.3 Enzyme attachment and Support Activation: 
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An activated support is defined as a material possessing an enzyme reactive functional 
group, which is covalently attached to a supposedly inert surface. Consideration of the 
stability of the resultant bond now existing between the enzyme and the support, the local 
environment of the enzyme as well as the potential loss of activity upon immobilization, 
are highly important. There are a number of procedures, which aid in the activation of 
support materials and each differs according to the type of support. Support activation for 
polysaccharides is through derivatization of available hydroxyl functions using reagents 
such as cyanogens bromide, epoxides triazine derivatives such as cyanuric chloride, 
sodium periodate or benzoquinone. It has been noted that polyacrylamide and its 
derivatives can be activated by their reactions with diamines while on the other hand, 
inorganic supports are commonly silanized and activated by reacting with glutaraldehyde. 
Other support activation mechanisms are diazotization or reaction with carbodiimides, 
thionyl chloride, N-hydroxysuccinimide or transition metal salts such as titanium 
chloride. The activated support is now suitable for covalently linking the enzymes and in 
most cases this is through direct reactions with available amino functions such as lysine 
residues as well as through thiols and phenol functions. Entrapment techniques for 
enzyme immobilization have been popular for quite some time but in the past few 
decades, covalent binding of enzymes to a suitable activated support has been by far the 
most common approach and hence the most useful technique. Later we will discuss the 
reason for the popularity of covalent binding as well as the other immobilization 
techniques (Worsfold et al, 1995). 
 
2.2.6 CHOICE OF IMMOBILIZATION METHOD: 
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Prior to the immobilization of an enzyme it is of extreme importance to choose the 
appropriate immobilization method, which is aimed at reactive groups outside the active 
catalytic and binding site of that enzyme. Knowledge of the active sites of a particular 
enzyme should be known in order to enable a choice from various methods that would 
avoid reaction with the essential groups therein. On the other hand, these active sites of 
the enzyme can be protected during the attachment process provided the protective 
groups can be removed without the loss of enzyme activity. 
The surface on which the enzyme is to be immobilized has several vital roles to play 
which include the retaining of tertiary structure in the enzyme by hydrogen bonding or 
the formation of electron transition complexes. Increasing the thermal state by the 
retention of the tertiary structure in the immobilized state of the enzyme is also important, 
therefore it is a requirement to examine and intensively follow new discoveries in the 
chemical nature of soluble thermostable enzymes. The immobilized enzyme together 
with the microenvironment of that particular enzyme possess an anionic or a cationic 
nature of the surface that has the ability to make a change in the optimum pH of the 
enzyme up to two pH units. In most cases it is together with a broadening of the pH 
region in which the enzyme can work effectively. The methods, which are associated 
with immobilization of enzymes, fall into four main categories as described in the 
following sections.  
 
 
 
2.2.6.1 Physical Adsorption: 
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Physical adsorption of an enzyme onto a solid support is the simplest method for 
immobilising enzymes. This method involves a non-specific physical interaction between 
the enzyme in use and the surface of the support as a result of mixing a concentrated 
enzyme solution with the solid. The binding is mainly by hydrogen bonds, multiple salt 
linkages and the Van der Waal’s forces, causing this method to be less disruptive towards 
the enzyme as compared to chemical means of attachment. The major advantage of 
adsorption is that there are no reagents required and only a minimal number of activation 
steps are required. The weak bond involvement between the enzyme and the support is 
sometimes a problem mainly caused by changes in temperature, pH, ionic strength or the 
presence of a substrate, thereby resulting in the desorption of the enzyme. Non-specific 
adsorption of other enzymes or substances is also another disadvantage, since as the 
immobilized enzyme is used, its properties are altered. If the substance adsorbed is the 
substrate for the enzyme, then the rate usually decreases but this depends on the surface 
mobility of the enzyme and the substrate. Adsorbed enzymes have been temporarily 
stabilized and this has been achieved by cross-linking the enzyme in a chemical reaction 
subsequent to its physical adsorption. 
This type of immobilization technique has been used for the immobilization of 
horseradish peroxidase (HRP) on totally cinnamoylated derivatives of D-glucosome and 
D-Manitol in the form of glassy beads. The immobilization of this enzyme on these 
supports involved an intense hydrophobic interaction between the cinnamoyl groups of 
the support and the enzyme. The polymerisation and cross-linking of the derivatives was 
achieved by irradiation in the ultraviolet region, where these compounds showed 
maximum sensitivity. It was discovered that the immobilized enzyme was more resistant 
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to inactivation by hydrogen peroxide and also to heat at neutral pH. Several aspects, 
which included HRP concentration, support concentration, immobilization time and pH, 
were studied in order to find the best immobilization conditions (Rojas-Malgarejo et al, 
2003). 
Physical adsorption was also used to immobilize polyelectrolyte-stabilized enzymes into 
activated macroporous and conductive carbon material for the construction of stable 
biosensors. Polyelectrolytes used in this case were polyethylenimine and 
diethylaminoethyl-dextron. Polyethylenimine is responsible for the stabilization of the 
secondary structures of various enzymes thus preventing denaturation. It also prevents the 
oxidation of enzymes sulphide groups prohibiting its inactivation and stability. The 
enzymes used in this work were lactate oxidase, tyrosinase, fructose dehydrogenase, 
pyranose oxidase and pyruvate oxidase, which were stabilized to carbon paste before 
being immobilized on the carbon material, which served as the immobilization matrix as 
well as the electrochemical transducer (Dimakis et al, 2002). 
 
2.2.6.2 Occlusion: 
This method of enzyme immobilization involves the confinement of enzymes within 
lattices of polymerised gels allowing the free diffusion of low molecular weight 
substrates and reaction products. A hydrophilic matrix is polymerised in an aqueous 
solution of the enzyme and is later broken up to the desired particle size. There is no bond 
formation existing between the enzyme and the polymer matrix, therefore there is no 
enzyme disruption making occlusion also an applicable method. A disadvantage of this 
method is that only low molecular weight substrates diffuse to the enzyme  thus making 
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this method suitable for enzymes such as trypsin, ribonuclease, dextronase, etc which act 
on macromolecular substrates. Upon polymerisation, free radicals are generated which 
also cause problems by affecting the activity of the entrapped enzyme. It is always 
advised that the entrapped enzyme should be cross-linked with glutaraldehyde in order to 
prevent leakage of the enzyme as a result of the broad distribution in pore size of the 
synthetic gels especially of the polyacrylamide type. Finally, occlusion of the enzyme can 
be achieved by using ultra filtration membranes of well-defined pore sizes. 
This technique was used to immobilize D-fructose-5-dehydrogenase onto a platinum 
electrode to produce a biosensor, which was used for the fructose detection. The 
immobilization was done in polypyrrole film where sodium ferricyanide was used as the 
mediator for the system (Garcia et al, 1998). 
Occlusion was also used in a study, which involved the immobilization of the enzyme 
ascorbate oxidase in a graphite/epoxy electrode in a poly (ethylene-co-vinyl acetate) 
matrix. After subsequent preparation, enzyme immobilization was achieved with the aid 
of glutaraldehyde (Fernandes et al, 1999). 
 
2.2.6.3 Cross-Linking: 
Generally, the immobilization of enzymes using this technique is achieved by 
intermolecular cross-linking of the enzyme either to another enzyme or to the functional 
groups of an insoluble support. Cross-linking an enzyme to itself is extremely expensive 
and insufficient due to the fact that some of the enzymatic material will act mainly as the 
support, resulting in a relatively low enzymatic activity. This method is best utilized in 
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relation with one of the other mentioned methods. It is advantageous in a way because it 
prevents leakages from polyacrylamide gels but most importantly, it is used as a means of 
stabilizing adsorbed enzymes. 
This method was used for the immobilization of the enzyme tyrosinase (Tyr) in the 
presence of the mediator NQS for the determination of dichlorvos organophosphate 
pesticides. The activity of Tyr is based on the ability to reduce the quinone form of the 
mediator NQS to the reactive o-diol form substrate of Tyr (H2NQS) at the working 
electrode, thus allowing modulation of the catalytic activity of the enzyme and 
measurement of the inhibition produced by the pesticides (Vidal et al, 2006). 
In another study, an amperometric biosensor for the determination of hydrogen peroxide 
was developed based on cross-linking horseradish peroxidase with the aid of 
gluataraldehyde with MWNTs/chitosan composite film coated on a glassy carbon 
nanotube/chitosan composite film coated on a glassy carbon electrode (Quian et al, 2001) 
 
2.2.6.4 Covalent Binding: 
The formation of covalent bonds between the enzyme and the solid support is the most 
intensely studied of the immobilization techniques. The type of reaction by which a 
particular enzyme should be immobilized is chosen with regards to the fact that the 
binding reaction should be performed under conditions that would not cause the loss of 
enzymatic activity, and that the enzyme active site must be unaffected by the utilized 
reagents. The functional groups of enzymes, which are suitable for covalent binding 
under mild conditions, include: 
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(i) The alpha amino groups of the chain and the epsilon amino groups of lysine 
and argine  
(ii) The alpha carboxyl group of the chain and the beta and gamma carboxyl 
groups of aspartic and glutamic acids  
(iii) The phenol ring of tyrosine  
(iv) The thiol group of cysteine.  
There are only a small number of reactions which have been designed to couple with 
functional groups on the enzyme other than the amino and phenolic residues. Similar to 
cross-linking, covalent-binding provides stability as well as insolubilized enzyme 
derivatives that do not leach the enzyme into the surrounding solution. 
Covalent binding was the method used in a project whereby two biosensors were 
prepared for oxalate determination using two enzymes respectively, namely oxalate 
oxidase  and horse radish peroxidase which were incorporated into carbon paste modified 
electrode with silica gel coated with titanium oxide containing toluidine blue (Perez et al, 
2001). 
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2.2.7 CHARACTERISTICS OF  IMMOBILIZED ENZYMES: 
Factors such as activity and stability have a significant effect on immobilized enzymes 
and therefore, it is important that the percentage or the amount of immobilized enzyme 
together with the enzyme activity remaining after immobilization should be stated along 
with the experimental conditions which are well suited for the determination. The activity 
of the enzymes is the most important information for the comparison of immobilization 
techniques and is often not available. It is vital that one knows the amount of enzyme 
immobilized onto a support and this is usually achieved by measuring the amount of 
enzyme remaining in the supernatant after immobilization and then subtracting this from 
the amount which was originally present. There is a fraction of difficulty in the 
determination of absolute activity of the enzyme on the support material after 
immobilization; therefore the apparent activity is measured which involves the mass 
transfer as well as diffusional restrictions in the experimental method being used 
(Worsfold et al, 1995).  
The stability of the immobilized enzyme with respect to time, temperature, storage 
conditions and at times experimental variables are critical performance indicators that 
should be noted. There are various methods in which this can be addressed however the 
recommended and most popular is the storage of the enzyme under normal operating 
conditions also known as the ambient temperature in the appropriate buffer solution. 
After a fixed time period the activity of the enzyme is monitored following the same 
procedure as that for the determination of the enzyme activity after immobilization. Each 
enzyme has its own lifetime and maximum analyses strength. To account for the 
efficiency of a particular enzyme, the effect of introducing synthetic standards, reference 
material, as well as the introduction of samples at predefined intervals and frequencies 
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should be determined prior. Consideration should also be placed on what the effect would 
be on the enzyme during the immobilization step by paying special attention to aspects 
such as pH, temperature, ionic strength and the incorporation of impurities during the 
procedure. The optimum pH, oxidation and reduction working range and the apparent 
Michaelis constant for the appropriate substrate of an immobilized enzyme, could all be 
affected by immobilization and the experimental conditions therefore; prior knowledge of 
the details of the experiment should be noted (Worsfold et al, 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 CYTOCHROME P450 (2D6): 
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The sensing enzyme used in this study is Cytochrome P450 (2D6). In this section, the 
structure, biochemistry and the reaction kinetics of this enzyme will be discussed. 
2.3.1 Occurance of the enzyme: 
Iron Porphyrin enzymes also known, as cytochromes were first investigated by Warburg 
and at the time they were referred to as cell pigments. It was discovered that carbon 
monoxide had the inhibitory factor on respiration cells in the dark, however upon 
illumination, respiration was resumed. Since it was known that iron-carbon monoxide 
complexes were photo-dissociated, Warburg then suggested that in respiration a 
compound of iron was involved. The photo effect was examined more closely and it was 
discovered that a specific wavelength was involved which was a characteristic absorption 
wavelength of iron hema-chromogen containing porphyrins. Warburg then came to the 
conclusion that the respiratory pigments were similar to these compounds (Key et al, 
1966).  
MacMunn later continued the study on these compounds but it was Keilen who revisited 
his work who discovered that at specific wavelengths a pigment was absorbed in several 
cells, which were then given the name cytochrome. Therefore, all the cells, which were 
examined and contained this pigment, could be readily observed on reduction due to a 
change in light absorption. CYP 2D6 was discovered fifty years ago among multiple 
pigments of 450nm (Key et al, 1966). However, approximately ten years ago, the first 
gene to code for a specific CYP enzyme was isolated. A number of these genes were 
isolated which were used to produce the enzymes in their most purified forms hence; 
their amino acid sequences could be determined (Hermeryck at al, 2002). 
2.3.2 Cytochrome P450-2D6 (CYP2D6: 
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CYP 2D6-P450 (CYP2D6) forms part of a muligene family of heme enzymes which have 
the ability to catalyse the NADPH – dependant monoxygenase as well as other reactions 
of different exobiotic and endobiotic liphophilic substrates. These enzymes are capable of 
metabolizing over 1,000,000 chemicals and undergo mono-oxygenation reactions which 
are very useful as they are responsible for the hydroxylation of a number of compounds 
including steroids, fatty acids, drugs, food additives, fungi, bacteria, (Harris et al, 2001; 
Subehan et al, 2006) alkanes and polyaromatic and polychlorinated hydrocarbons. 
Amoung the biotransformation reactions of CYP2D6 included are N-, O-, or S-, 
demethylation, dealkylation , S- oxidation, Epoxidation, Aliphatic oxidation, Reductive 
Dehalogenation and Sulfoxide formation (Shumyanteva et al, 2005; Bistolas et al, 2005). 
In man most of the CYP2D6 is found in the liver which is the main organ involved in 
processes of drug and toxin removal. A remarkable amount of this enzyme is also found 
in the small intestine but usually CYP2D6 sits around the microsomal part of the 
cytoplasm in the endoplasmic reticulum, as well as in mitochondria (Iwuoha et al, 1998). 
The enzymes isolated from mitochondria are known as Steroidogenic CYP2D6 enzymes, 
which are situated in single, cell organisms and are phylogenetically older. They usually 
consist of an iron-sulphur protein, NADPH and NADH-dependant reductase (on FAD-
type flaovoprotein) and P450 enzyme. Steroidogenic enzymes are responsible for steroid 
synthesis as well as other substances which are required for maintaining the cell wall 
integrity. Another form of these enzymes is Xenobiotic CYP2D6 enzymes, which has 
evolved from Steriodogenic CYP2D6 enzymes over one billion years ago. The term 
Xenobiotic is based on the fact that these enzymes have the ability to metabolise foreign 
biological substances. They are located in the smooth endoplasmic reticulum of cells, 
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while some studies indicate that they have evolved during the period of plant-animal 
differentiation. These enzymes are known to be constituted by NADPH: P450 reductase 
(FAD-and FMN- containing flavoprotein) and P450 enzyme (Iwuoha et al, 2003, Lewis 
et al, 2002).  
 
2.3.3 Kinetics of Catalytic Reaction: 
The active site of CYP 2D6 is the iron-protoporphyrin IX that consists of an axial thiolate 
of a cysteine residue as the fifth ligand. The metal iron exists in two oxidation states 
namely; Fe2+ and Fe3+. Almost all iron complexes are octahedral and practically all are 
paramagnetic which is due to the unpaired electrons in the 3d orbital. As mentioned 
before, heme (Fe2+) enzymes exhibit characteristic visible absorption spectra due to the 
presence of protoporphyrin IX. However, their spectra differ according to the identities of 
the lower axial ligands donated by the protein and the oxidation state of the iron, as well 
as the identities of the upper axial ligands donated by the substrates (Harris et al, 2001).  
At the initial stage of the catalytic cycle of CYP2D6, the active site, which is the iron-
protophyrin, has an axial thiolate of a cysteine residue as the fifth ligand. The enzyme at 
this point is in the hexa-coordinated low spin ferric form (Fe3+) possessing water as the 
sixth ligand. CYP2D6 is now said to be resting since it is in the ferric form (Shumyanteva 
et al, 2005).  Substrate hydroxylation with the aid of the CYP2D6 mono-oxygenase 
results in the insertion of an oxygen atom into the substrate denoted by RH. The second 
oxygen atom is then reduced to water while ROH is formed as a result of the 
consumption of two reducing equivalents (Lewis et al, 2002). This can be summarized as 
follows: 
RH + O2 + 2e- + 2H → ROH + H2O 
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The source of electrons in this type of system is from flavoproteins, ferrodoxin like 
proteins, NADPH (Lewis et al, 2002), the mediator or an electrode. The mechanism for 
substrate hydroxylation by CYP, which is generally accepted, involves the following 
steps although there are still several details that still remain unsolved. When the substrate 
binds to the hexa-coordinated low-spin ferric enzyme, water is excluded from the active 
site, thereby resulting in a change in the 5-coordinate low spin state. This causes a 
decrease in polarity which is accompanied by a positive shift (Bistolas et al, 2005) or 
lowering of the redox potential by 110 mV to 130 mV which makes the first electron 
transfer step thermodynamically favourable, from its redox partner NADH or NADPH 
(Shumyanteva et al, 2005). The transfer of the first electron from one of the redox 
partners reduces the ferric iron to the ferrous enzyme and this process is called reduction. 
This form of the enzyme can now bind molecular oxygen resulting in a ferrous-dioxygen 
(FeII – O2) complex. A second electron transfer takes place along with a proton gain 
forming an iron-hydroperoxo (FeIII-OOH) intermediate (Bistolas et al, 2005). The O22- 
reacts with two protons from the surrounding solvent, thus breaking the O-O bond to 
release a water molecule and a highly active iron-oxoferryl intermediate. One hydrogen 
atom is abstracted from the substrate by the intermediate to produce a one electron 
reduced ferryl species (FeIV-OH) and a substrate radical. On the other hand, the ferryl 
species reacts with the C – H bond of the substrate in a concerted reaction without the 
radical intermediate formation. The final step of the process is the formation of the 
enzyme product complex and the release of the product denoted ROH. The low-spin state 
of the enzyme is then regenerated (Bistolas et al, 2005). The reaction mechanism of this 
enzyme is illustrated in the following scheme: 
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Scheme 2.2:  Reaction mechanism of CYP450 (2D6) 
 
2.3.4 Classification of Cytochrome P450 enzymes: 
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Different enzymes have certain similarities such as amino acid sequence homology, 
which then resulted in the development of a classification system for enzymes. The basis 
of this classification is based on the principle that, the more similar the structure of the 
enzymes, the more closely are they both phylogenetically and functionally. The CYP 
enzymes are grouped into families that are represented by the first number; example in   
P450 (2D6) the first number is represented by 2. The idea behind this grouping is based 
on the fact that all the enzymes in the same family have at least 40% amino acid sequence 
homology. These families are then further grouped into subfamilies where at least 55% of 
the amino acid sequences are homologous among the enzymes. There are at least 74 CYP 
families with only 17 of these described in man. The subfamilies are denoted by an 
alphabetical letter which in P450 (2D6) is D. The last number which in P 450 (2D6) is 6 
represents the gene that codes for the enzyme. There are about 30 of these described in 
man. The following is a table showing all of the human CYP enzymes grouped into 
families and subfamilies. 
Table 2.5:  CYP Enzymes as classified by family, subfamily and gene 
1A1 2A 6 3A3/4 4A9 7 11A1 17 19 21A2 27 
1A2 2A7 3A5 4B1  11B1     
 2B 6 3A7 4F2  11B2     
 2C 8  4F3       
 2C 9         
 2C18         
 2C19         
 2D 6         
 2E 1         
 2F1         
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2.4   SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS  
                                                  (SSRIs): 
Depression is a recurrent illness, in which the neurotransmitter, serotonin is affected. This 
condition affects both the economic as well as the social functioning of the individual 
patient thus leading to suicidal behaviour (Pedrazza et al, 2007). Tricyclic 
antidepressants have been used for the treatment of this condition between the years 1960 
to 1980; however the increased side effects associated with these drugs have lead to 
diagonised patients to end treatment (Malfara et al, 2007). The need for new drugs with 
minimal side effects then resulted in the development of selective serotonin re-uptake 
inhibitors (SSRIs). These drugs function by enhancing serotogenic transmission and 
inducing down-regulation of postsynaptic receptors (Murrin et al, 2007). The most 
commonly prescribed SSRIs used for the treatment of depression are fluoxetine, 
fluvoxamine, paroxetine, sertraline and citalopram. All these drugs have a similar affect 
in terms of antidepressant treatment as well a similar side-effect pattern. The only 
difference among these drugs is in their metabolism, chemical structure and 
pharmacokinetic properties (Hermeryck et al, 2002). 
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2.4.1 Fluoxetine: 
O
CF 3
NH
CH3
 
Scheme 2.3: Structure of fluoxetine prior to metabolism 
 
Fluoxetine (scheme 2.3) is a bicyclic derivative of phenyl-proplamnie [D,L-N-methyl-3-
phenyl-3-(α,α,α-trifluoro-p-toyloxy)-polyamine hydrochloride] whose metabolism is 
responsible for N-demethylation to norfluoxetine (Kovacevic et al , 2006; Vlase et al, 
2005). Fluoxetine is used in the treatment of obsessive-compulsive disorder, panic 
disorder, premenstrual dysphoric disorder and bulimia. A low level of serotonin is 
currently seen as one of the neurochemical symptoms of depression; therefore this drug is 
designed to elevate the level of the presynaptic cell. Fluoxetine is said to be selective 
because it has a weak effect on the other monoamone transporters, thus it has a little 
influence on the level of the other neurotransmitters (Heimke et al, 2000). 
In most countries, this drug was the first SSRI that became available for clinical use. It is 
a racemic mixture of two enantiomers, in which the S-enantiomer is approximately 1, 5 
times more potent than the R-enentiomer. It undergoes extensive metabolic conversion 
resulting in the active metabolite norfluotine as well as multiple other metabolites. The 
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pharmacological difference among the enantiomers is even more evident for the 
metabolite norfluoxetine. The S-enantiomer is found to have approximately 20 times 
higher reuptake blocking potency than the R-enantiomer. This drug is absorbed orally 
and it is almost completely absorbed in the human system. After oral administration, 
fluoxetine is mainly excreted in urine, with less than 10% excreted unchanged or as 
fluoxetine N-glucuronide. The metabolism of this drug is illustrated in scheme 2.4. 
 
O
CF3
NH
CH3
O
CF3
NH
H
CYP 2C9
 CYP 2D6
CYP 2C19
CYP 3A4
FLUOXETINE NORFLUOXETINE
FLUOXETINE 
GLUCURONIDE
OTHER METABOLITE 73%
NORFLUOXETINE 
GLUCURONIDE
 
 
Scheme 2.4: Metabolism of fluoxetine by izoenzymes 
 
A number of studies have investigated the metabolism (scheme 2.4) of Fluoxetine and 
have found the CYP isoenzymes to be responsible for the metabolism. From in vitro 
 50
 
 
 
 
studies, it has been suggested that CYP2C9 plays vital role in the N-demethylation of 
Fluoxetine. CYP2C19 and CYP3A4 have been also found to play a similar role while that 
of CYP2D6 was found to be negligible. On the other hand, the clearance of R- and S- 
fluoxetine as well as S- norfluoxetine, have been shown to be strongly dependant on 
CYP2D6 (Heimke et al, 2000).  
The most prominent feature of all SSRI’s is their potential and ability for 
pharmacokinetic drug interaction with other classes of drugs. This type of interaction was 
first reported for fluoxetine and relevant clinical interactions have been observed for 
TCAs as well as neuroleptics. The inhibitory effects of fluoxetine and norfluoxetine on 
the isoenzyme CYP2D6 could be the cause of the metabolism of these interactions, with 
the extent of inhibition together with the plasma concentration of fluoxetine and 
norfluoxtine respectively. Therefore, this suggests that fluoxetine and norfluoxetine are 
able to compete with other drugs for metabolism by CYP2D6 (Heimke et al, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 51
 
 
 
 
2.4.2 Fluvoxamine: 
CF 3
N
O
NH2 O
CH3
  
                               Scheme 2.5:  Structure of fluvoxamine prior to metabolism 
 
Fluvoxamine (scheme 2.5) became popular in 1999 after it was discovered that one of 
two teenage shooters who was involved in the Columbina High School massacre, was on 
this medication for the treatment of depression. At this point, the public as well as other 
economic sectors was pointing fingers at fluvoxamine and its manufacturer, Solvey 
Pharmaceutical, due to the fact that its clinical traits indicated that the drug had the ability 
and propensity to enhance mania in only 4% of the youth who took it. 
Fluvoxamine is also a selective serotonin reuptake inhibitor that is used primarily to treat 
depression, anxiety and Obsessive Compulsive Disorder. This drug functions by blocking 
the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, 
thereby enhancing the actions of serotonin on 5 HT1A autoreceptors. Its effects are similar 
to other SSRIs but it acts differently on the neurochemistry of the body. The difference is 
most beneficial to patients who experience usual or limiting side effects from other 
antidepressants. As compared to other SSRI’s, fluvoxamine has been found to cause a 
fewer side effects, especially in terms of loss of sex drive. Examples are the 
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gastrointestinal effects of which nausea is the most common, but it is mild and moderate 
(Kovacevic et al, 2006; Vlase et al, 2005). As seen for other SSRIs, the main route for 
elimination of Fluvoxamine is through hepatic metabolism that includes oxidation 
demethylation and oxidative deamination shown in scheme 2.6. After fluvoxamine 
ingestion, eleven metabolites have been detected in urine, nine of which could be 
structurally identified. The majority of these metabolites were acids, which are likely to 
possess pharmacological activity. The biotransformation of fluvoxamine has been 
associated with the polymorphic activity of CYP 2D6 and CYP 1A2, but under the same 
conditions, the polymorphic isonzyme CYP 2C19 was not seen to play any role. 
In vivo studies have indicated fluvoxamine to inhibit CYP 2C19, CYP 3A4 and CYP 
2C9. The widespread inhibitory effects of this drug is concentrated on a common 
inhibitory mechanism, perhaps by fluvoxamine interaction or one of its metabolites 
possessing a heme moiety of the cytochromes. The inhibition of several CYP isoenzymes 
by fluvoxamine indicates that drug-drug interactions are clinically more critical than 
those of fluoxetine and paroxetine. In vitro studies of fluvoxamine indicate that it is a 
potent and a selective inhibitor of neuronal serotonin reuptake and has only very weak 
effects when associated with norepinephrine and dopamine neuronal reuptake (Perez et 
al, 2001; Kovacevic et al, 2006; Vlase et al, 2005). 
It has been discovered that fluvoxamine is often much safer than the other available SSRI 
medications. Investigations have shown that the chronic administration of fluvoxamine 
caused a downregulation to the brain norepinephrine receptors, as compared with other 
drugs, which are effective in the treatment of major depression disorders. The properties 
of fluvoxamine, which include antidepressant, anti-obsessive compulsive and anti-
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bulimic actions are assumed to be associated to its inhibition of the central nervous 
system neuronal uptake of serotonin. Some studies have shown fluvoxamine to have a 
more beneficial effect on suicidal ideation and or anxiety or somatic complaints as 
compared with impramine, dothiepin and maprotiline (Schreiber et al, 2006).  
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Scheme 2.6: Metabolism of fluvoxamine by izoenzymes 
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2.4.3 Sertraline: 
 
Cl
Cl
NH
CH3
 
 
Scheme 2.7:  Structure of sertraline prior to metabolism 
 
Sertraline (scheme 2.7) or sertraline hydrochloride is an antidepressant of the selective 
serotonin type, which possesses two ciral centers (Heimke et al, 2000). Medically, 
sertraline is used for the treatment of depression and anxiety but is also prescribed for the 
treatment of Obsessive Compusive Disorder, post-traumatic stress disorder, premenstrual 
dsphoric disorder, panic disorder and bipolar disorder. Some of the adverse conditions 
involving sertraline include insomnia, confusion, dizziness, tremors, asthenia and 
decreased libido. This drug is the second most potent inhibitor of serotonin reuptake as 
well as the second most selective blocker of serotonin over noradrenaline uptake. It has a 
low affinity for neurotransmitter receptors but has an exception for α1-adrenoceptor 
blocking potential. In rats Sertraline administered chronically attenuates phencyclidine-
induced locomotor hyperactivity, therefore on dopaminergic neurons, sertraline should be 
considered although the interaction is still obscure (Heimke et al, 2000, Pedrazza et al, 
2007). 
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Elimination of sertraline is though hepatic metabolism illustrated in scheme 2.8 but from 
an oral dose 0.2% is excreted unchanged in urine, but the metabolism has been 
discovered to be limited. The main metabolic step is N-methyation and the N-
demethylated metabolite is eliminated more slowly with a three time longer half-life than 
the parent drug. The plasma concentation of N-desmethylsertraline is calculated to be one 
to three times that of sertraline and the contribution to clinical effects can be neglected 
due to the fact that N-desmethylsertraline has only 5-10% of the serotonin reuptake 
inhibitor potency of sertraline. The N-demethylation has been discovered to be related to 
the activity of CYP 3A4 suggesting that this enzyme is involved. Sertraline is a substrate 
of CYP 3A4 suggesting that there is metabolism of this drug in the gut. This metabolism 
has not been examined in the gut and therefore little has been reported on other pathways 
which include oxidation at the side chain to a carbamic acid as well as oxidation 
deamination to a ketone derivative. Our study is the first to report the use of CYP 2D6 for 
the metabolism of sertraline where very low concentrations of this drug was analysed 
(Heimke et al, 2000; Zawertailo et al, 1995). 
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Scheme 2.8:  Metabolism of sertraline by izoenzyme 
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2.4.4 Paroxetine: 
O
O O
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Scheme 2.9:  Structure of paroxetine prior to metabolism 
 
The pharmaceutical company GlaxoSmithKline released paroxetine in 1992 and 
prescribed it for depression and other related diseases. It is a phenylpipenidine derivative 
and is the second most prescribed antidepressant due to its most potent inhibition of the 
reuptake of serotonin; 5-HT, as compared to all the currently available antidepressants 
including other  SSRIs (Najeem et al, 2004). It is a very weak inhibitor of norepinephrine 
uptake but it has been found to be more active at this site when compared to other SSRIs. 
In terms of selectivity, paroxetine (scheme 2.9) has a high uptake inhibition ratio of 
norpinephrine to serotonin of all the SSRI’s (Bourin et al, 2001). Since paroxetine is a 
phenylpiperidine derivative, it is chemically unrelated to the tricyclic or tetracyclic 
antidepressants; therefore it has a low affinity for dopaminergic, catecholaminergic or 
histaminergic systems, thereby resulting in a low propensity to cause central and 
autonomic side effects. Paroxetine is an inhibitor of cytochrome isoenzyme P450 2D6. 
This drug is absorbed orally and it is able to undergo first pass metabolism that is 
partially saturable and its metabolites are found to be pharmacologically inactive in vivo. 
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The pharmacokinetics of paroxetine in adults, the young as well as well as the elderly 
possessing higher plasma concentrations is found to have a wide variation. Just like all 
other lipophilic psychotropic drugs, the metabolism of paroxetine (scheme 2.10) takes 
place in the liver with the aim of forming more hydrophilic excretable compounds. This 
metabolism includes oxidative cleavage of the methylenedioxy bridge, thereby resulting 
in an unstable catechol intermediate that is further methylated in the meta position to the 
meta-methoxyderivative or otherwise in the para-position to the para-methoxyderivative. 
Both of these metabolites are further conjugated with sulfuric acid or glucuronic acid but 
none of them is assumed to have a contribution to the pharmacological effects of 
paroxetine (Heimke et al, 2000). 
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Scheme 2.10:  Metabolism of paroxetine by izoenzymes 
 
 61
 
 
 
 
2.4.5 Citalopram:  
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Scheme 2.11:  Structure of citalopram prior to metabolism 
 
Citalopram (CIT) (scheme 2.11) is also an antidepressant drug of the group of selective 
reuptake inhibitors (Rochat et al, 1998), also used in the treatment of depression but that 
associated with mood disorders. The metabolism (scheme 2.12) of CIT leads to two 
pharmacologically active metabolites with the main one being N-desmethycitalopram 
which is also further demethylated to didesmethycitalopram. Besides the N-methylated 
metabolite, an N-oxide and a propionic acid derivative have also been identified. The 
propionic acid derivative is pharmacologically inactive therefore it does not possess any 
5-HT reuptake inhibiting activity. As a racemate, CIT has its pharmacology effects 
almost exclusively located in its S-(+) enantiomer, but the plasma concentration of the 
inactive R-(-) enantiomer are higher than those of the S-(+) enantiomer. The S/R 
enantiomer ratio of CIT is 0.56 in patients and 0.72 for desmethylcitapram (Rochat et al, 
1998; Heimke et al, 2000). 
The polymorphically expressed isoenzymes, CYP2C19 and CYP2D6, have recently been 
discovered to be involved in the biotransformation of CIT. The N-methylation works in 
conjuction with mephenytoin hydroxylase activity and in poor metabolizers of 
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mephenytoin that lack CYP2C19 activity, the total clearance as well as N-methylation 
clearance being lower than in EM of CYP2C19. 
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Scheme 2.12:  Metabolism of citalopram by izoenzymes 
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The S/R ratio of the CIT enatiomers have been suggested to be indicative of the activity 
of CYP2C19, while CYP2C19-deficient patients possessing an almost doubled CIT S/R 
ratio of greater than 1. However, the N-methylation of desmethycitalopram to 
didesmethylcitalopram relies on CYP2D6 was detected in poor metabolizers (PM) of 
sparteine and the AUC’s of desmethylcitalopram were about a third higher in poor 
metabolizers than in extensive metabolizers (EM). Poor metabolizers are a group of 
individuals which possess a severely impaired CYP2D6 catalytic capacity while 
extensive metabolizers are a group of individuals with a normal CYP2D6 catalytic 
function (Hemeryck et al, 2002). In vitro studies have however concluded CYP3A4 to be 
involved in N-demethylation of CIT, which has been indicated by accelerated metabolism 
of citalopram under treatment with carbamazepine. After the involvement of these 
isoenzymes on the metabolism of CIT, their activities are affected. The activity of 
CYP2D6 is reduced slightly after chronic treatment with CIT, which is probably due to 
inhibitory properties of N-desmethylcitalopram. There is no effect found on the 
pharmacokinetics of the substrates of CYP2C19. With other psychotropic drugs, which 
include TAC’s, neuroleptics and tranquilizers; there are rather unlikely pharmacokinetic 
drug interactions. Therefore, CIT is the safest SSRI when it comes to pharmacokinetic 
drug interactions (Moller et al. 2000; Heimke et al, 2000).   
In 2003, the patent for citalopram expired, and a new SSRI drug called Escitalopram 
(ESC) (scheme 2.13) was produced derived from the S-enantiomer of CIT ( LoVecchro et 
al, 2006). 
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Scheme 2.13:  Structure of escialopram prior to metabolism 
 
This drug also functions as CIT, which is to treat depression associated with mood 
disorders apart from anxiety and body dysmorphic disorder (LoVecchro et al, 2006). ESC 
is presumed to be more potent towards serotonergic activity in the central nervous system 
(CNS), as a result of the inhibition of CNS neuron serotonin uptake. When compared to 
its R-enantiomer, ESC is found to be 100 times more potent when it comes to 5-HT re-
uptake inhibition. ESC is metabolized by CYP3A4, CYP2C19 and CYP2D6 izozymes in 
the liver which are responsible for the ESC metabolism to its main metabolite, S-
demethylcitalopram (S-DCIT). Generally, ESC is well tolerated by patients apart from 
the more frequent side effects such as nausea; while others include insomnia, dry mouth, 
constipation and diarrhoea. 
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2.4.6 Zimelidine: 
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Scheme 2.14: Structure of Zimelidine 
 
Zimelidine (scheme 2.14) was the first selective serotonin reuptake inhibitor anti-
depressant to be produced and this was done in the early 1980’s. The development of 
zimelidine was as a result of a search for drugs with similar structures to 
chlorpheniramine, which is an antihistamine with antidepressant activity. 5-
Hydroxytryptamine neuronal uptake has been established to be inhibited by zimelidine as 
well as its active metabolite, norzimelidine, both in vitro and in vivo but having a much 
lesser effect on noradrenaline uptake. In a conducted research with rats, it was found that 
zimelidine in vivo blocked the 5-HT reuptake mechanism in the cerebral cortex, 
hippocampus, striatum, hypothalamus and spinal cord, thereby indicating an effect on 
both the ascending and descending 5-HT pathways. It was noted that ZIM failed to 
reduce NA turnover even high doses, but it was able to reduce 5-HT turnover in very low 
doses in the rat. In mice, however, the 5-HT mediated behaviours were enhanced in doses 
related to the inhibition of 5-HT uptake. When compared to amitriptyline and mianserin, 
zimelidine displayed a 5-HT receptor blocking action in vitro, but only at extremely high 
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doses but failed to block 5-HT mediated behaviour. When it came to histamine H1 and H2 
receptors, zimelidine avoided any action towards them, but had a negligible impact on 
noradrenergic alpha 1-and alpha 2- receptors as well as on beta-receptors. Long term 
treatment with zimelidine did not cause any attenuation of the 5-Ht uptake blocking 
potency or the reduction of 5-HT turnover. Meanwhile, this treatment reduced the 
number of beta-receptors in the brain. On the other hand, a repeated zimelidine treatment 
increased a new 5-HT receptor site characterized by a low affinity and with a high 
number of binding sites, which resulted in a decrease in the number of high affinity 5-HT 
receptor binding sites. 
Therefore the resultant conclusion was that ZIM has an effect on the presynaptic 5-HT 
reuptake mechanism but has a neglible action on morodrenergic, acetycholine, 5-HT and 
histamine receptors in the brain (Ogren et al, 1981). This action leads to a fatal condition 
affecting the central and or pheripheral neuropathy known as Guillain-Barre Syndrome, 
which caused the drug to be banned worldwide. Another factor for its banishment was 
based on the fact that it cased a hypersensitivity reaction that involved many organs 
including skin exanthema, flu-like symptoms, arthralgas and sometimes eosinophilia. 
Zimelidine was also found to increase suicidal ideas and or attempts among its patients 
but after it’s banning, fluoxetine and fluvoxamine over took it, which have a reduction in 
this behaviour. 
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2.5 POLYMERS: 
Polymers are being neglected for their traditional roles as electric insulators to take new 
roles as conductors with a wide range of applications. Researches from different fields 
are in a process of combining expertise to study organic solids that posses remarkable 
conducting properties. Organic compounds with the ability of effectively transferring 
charge can be divided into three main groups namely; ion radical salts charge transfer 
complexes, organic species and conjugated conducting polymers. In the past two decades 
a new class of polymers known as intrinsically conducting polymers or electro-active 
conjugated polymers has emerged. These polymers have gained popularity due to their 
interesting electrical and optical properties, which have previously been observed only in 
inorganic systems. The ability to produce these materials in mild conditions has enabled a 
range of biological compounds to be incorporated into the polymer structures. The 
electronic properties are then observed in this instance to stimulate and allow a direct and 
interactive relationship with the biochemistries of the biological components to produce 
analytical signals. For a polymer to be regarded as a conducting polymer there should be 
an overlap of molecular orbital to allow the generation of delocalized molecular wave 
function (Ahaja et al, 2007; Malholtra et al, 2006). 
 
2.5.1 CONDUCTING POLYMERS: 
The chemical bonding in conducting polymers produces one unpaired electron where 
there is a π electron per carbon atom in the backbone of the polymer. The carbon atoms 
are π bonded in a sp2pz configuration where the orbital of successive carbon atoms 
overlap providing delocalization of the electrons along the backbone of the polymer. 
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Charge mobility is exerted along the backbone of the polymer as a result of this electron 
delocalization introducing properties such as electrical conductivity, low energy optical 
transitions, low ionization potential and high electron affinity. The π bonds in conducting 
polymers are highly susceptible to chemical or electrochemical oxidation or reduction 
processes. The formations of non-linear defects such as solitons, polarons and bipolarons 
produced either during doping polymerization of a polymer, have made a contribution to 
the electrical conduction in these polymer materials. An increase in electrode 
modification as a result of these polymers has provided new and interesting properties, 
which have contributed for the wide application of conducting polymers. They have been 
applied in electrocatalysis, rechargeable batteries, membrane separation, optoelectronic, 
chromatography and solar cells (Ahaja et al, 2007; Malholtra et al, 2006). 
 
2.5.2 SYNTHESIS OF CONDUCTING POLYMERS: 
There are various available methods for the synthesis of conducting polymers, with 
oxidative coupling of the monomer being the most widely used technique. This technique 
involves the formation of a cation radical followed by another coupling to produce a di-
cation and the repetition then leads to the polymer (Malholtra et al, 2006). Electro-
polymerization is normally carried out in a single cell compartment where a three-
electrode configuration is employed subjected to an electrochemical solution consisting 
of a monomer and a supporting electrolyte (in some case) all dissolved in an appropriate 
solvent which in some cases is an acidic. The polymerization can be carried out either 
potentiostatically where the potential is kept constant with a variation of the current with 
time, or galvanostatically by keeping the current constant thereby monitoring the 
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electrode potential. A three-electrode system employed during the polymerization 
comprises of a working electrode, a counter electrode and a reference electrode. Metals 
such a gold, platinum, carbon, nickel, titanium and palladium are used as working 
electrode and function as support systems for the polymer films. Counter electrodes on 
the other hand supply the current required by the working electrode. A few commonly 
used counter electrodes include metallic foils of nickel, platinum and gold. Reference 
electrodes such as SCE, NCE, silver and mercurous sulfate are used in aqueous media 
(Ahaja et al, 2007). 
Conductivity of the polymer is influenced by a number of factors including polaron 
length, the conjugation length, and the overall chain length and by the charge transfer to 
adjacent molecules. Research has proved that electrochemical synthesis is rapidly 
becoming the preferred method for polymer preparation due to the simplicity and 
reproducibility associated with this technique. One advantage associated with the 
electrochemical polymerization of conducting polymers is that their reactions can be 
carried out at room temperature either by varying the potential or the current and with 
time the thickness of the film can be monitored and controlled.  Besides copolymers and 
graft copolymers, electrochemical synthesis can be used for the generation of free 
standing, homogeneous and self doped films. Conducting polymers such as polypyrrole, 
polythiophene, polycarbazole, polyindole and polyazulene can be synthesized using this 
technique. 
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2.5.2.1 Polypyrrole: 
Polypyrrole is a conducting polymer which can be synthesized either chemically or 
electrochemically. Synthesizing this polymer electrochemically is advantageous since the 
polymer produced is better conducting and the conductivity is stabilized for a long period 
of time (Lakard et al, 2007). An applied current or voltage can control the location, 
morphology, thickness and chemical composition of polypyrrole. Chemical composition 
implies the use of a particular dopant during the synthesis. These dopants include heparin 
and heparin sulphate and their use is based on the fact that they have an ability to increase 
the conductivity of the polymer to a level of 103 S cm-1. This polymer is one the 
commonly used when giving examples of the manner in which conducting polymer 
behave. The polymerisation of this polymer mainly occurs on platinum electrode where a 
wide variety of enzymes are immobilized. The mechanism of polymerisation takes place 
at potentials above + 600mV.  There are a number of factors which affect the morphology 
of the film and they include the crystallographic structure of the underlying electrode, the 
nature of the electrolyte, the speed of the potential of deposition of the polymer known as 
the scan rate, the concentration of the monomer, the presence of anions and polyanions or 
in some instances surfactants and finally the pH of the solution.  
 
2.5.2.2 Polyindole: 
Another electroactive polymer is polyindole, which is synthesized by anionic oxidation of 
indole in various electrolytes. When indole is electrochemically oxidized in LiClO4 
containing acetonitrile electrolyte medium, an electrochromic polymer film with good air 
stability (Pandey et al, 1998) is produced. This polymer has a green colour in its doped 
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state and possesses an electrical conductivity in the range of 10-2 to 10-1 S cm-1 depending 
on the nature of counter anion. The polymer is closely structured to polypyrrole and 
polyaniline but its conductivity is lower than that of both these polymer although it has a 
better thermal stability than them. Indole derivatives are found abundantly in a variety of 
natural plants and possess various physiological properties and are potentially bioactive 
compounds. 
 
2.5.2.3 Polycarbozole: 
Polycarbazoles are another type of conducting polymers, but they are less studied than 
the former mentioned polymers. They are somehow of particular interest since they 
exhibit photoconductivity and electochromic properties. They are synthesized by two 
main procedures. The first method involves the activation of the carbon-halogen bond of 
3, 6-dihalogenated monomer in the presence of a zero valent nickel complex. The 
dehalogenative polycondensation can be carried either chemically or electrochemically 
and leads to well defined polymers with 3, 6-linkages. The second route is the most 
commonly used and involves the electrochemical of chemical oxidation of carbazole 
derivatives in solution (Fernandes et al, 1999). The electrochemical stability of this 
polymer was seen to be less when compared to those of other conducting polymers. 
However this property can be enhanced by decreasing the poly dispersity of the material 
(Tran-Van et al, 2002). 
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2.5.2.4 Polyaniline: 
Polyaniline (PANI) is a conducting polymer of the semi-flexible rod polymer family that 
is electrically synthesized in the presence of an acidic medium by anionic oxidation of the 
aniline polymer onto an electrode surface. This attachment of PANI on the electrode 
surface can be done either by chemical or electrochemical means. Electrochemical 
polymerization is though galvanostatic, potentiostatic or potentiodynamic means, offering 
the potential to incorporate a wider range of dopant ions, since the reaction can be carried 
out in the presence of an appropriate electrolyte rather than a chemical oxidant (Grennan 
et al, 2006).  This procedure allows for film property control such as morphology and 
thickness allowing this polymer to be the most commonly used in biosensor preparation. 
For the polymer to retain its conductive property in the presence of non-acid media, it is 
electrical neutral in the oxidized form of the polymer (Grennan et al, 2006; Naudin et al, 
1998). 
PANI is known for its very strong pH sensitivity exisiting between the half-oxidized 
emeraldine base (EB) and the emeraldine salt (ES) form of PANI, which is a reversible 
acid – base reaction. The electrochemistry of PANI is illustrated in Scheme 2.15 where 
the complex transformation of PANI is also shown. Therefore it is generally accepted that 
polyaniline has been observed to exist in three oxidation states namely: the half oxidized 
ES, the fully reduced leucoemeraldine (LEB) and the fully oxidized pernigraniline 
(PNB). ES can be obtained either by oxidation of LEB or by the protonation of EB and 
this form of the polymer is also electrically conducting (Lindfors et al, 2002). 
In biosensor development, polyaniline serves as a point of attachment of bioactive 
compound such as enzymes, antibodies etc. as well as a means of electron transport 
 73
 
 
 
 
between the electrode and the active site of the bioactive compound (Grennan et al, 
2006). 
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Scheme 2.15: The different forms of PANI namely; PNB, ES, LEB and EB 
 
 In this study 8-aninilo-1-napthalene sulfonic acid (ANSA) (scheme 2.16) was 
polymerized to produce poly (8-anilino-1-napthaene sulfonic acid) (PANSA). 
ANSA belongs to a family of substituted naphthalene’s which are normally used as 
fluorescent probes in the study of biologically active molecule structure. These 
compounds are moderately soluble in water but in most cases they prefer a more 
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hydrophobic environment (Catena et al, 1989). In one study ANSA was towards the 
construction of biosensors where it was immobilized respectively onto different kinds of 
glucose oxidases, and these biosensors where used towards the detection of glucose 
(Scognamiglo et al, 2004). 
 
N
H
SO3H
 
Scheme 2.16: Structure of 8-anilino-1-napthalene sulphonic acid 
In our study aniline substituted naphthalene was used and it is the aniline substitute which 
was polymerized and the sulphuric component attached to a gold electrode. The 
electrochemistry of PANSA was very observed to be similar to that of PANI as seen from 
the work of (Mathebe et al, 2004) although polymerization was carried out in different 
acid media. This work reports the fabrication and characterization of PANSA based 
biosensor incorporating the enzyme CYP2D6 for the detection of SSRIs. 
Since protonation does not contribute any electrons to the system for both the 
polymerization of aniline and 8-anilino-1-napthalene sulfonic acid, a modification of the 
structure is assumed for the increased conductivity in both polymers. In some instances 
polymerization is done in the presence of a dopant in which two types of local distortions 
are involved to aid in the explanation of the emergence of charge carriers.  The first is a 
polaron which consists of a local distortion of chain that has the capability of storing the 
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extra positive charge in which only a single nitrogen in the oxidized form is protonated. 
On the other hand, a bipolaron has a similar local distortion in which imine nitrogens are 
protonated. Both of these distortions are coupled to the vibrations of the chain so that 
they are able to move along the polymer chain (de Oliveira et al, 2000). 
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2.5.3 APPLICATIONS OF CONDUCTING POLYMERS IN    
                                        BIOSENSORS:                                   
The increased number of governmental, academic and industrial laboratories involved in 
the research and assessment of the possible application of conducting polymers has 
shown this area to be in interdisciplinary in nature. The organized molecular structures of 
conducting polymers on metal substrates have attracted much attention largely due to 
their wide application in lightweight batteries, solar cells, molecular electronic devices 
and sensors. These polymers seek to function as three-dimensional matrices for the 
immobilization of active biological components thereby preserving a long duration for 
their activity. This observed property of conducting polymers together with their 
functionality as a membrane, has promoted an investigation toward the development of 
sensors (Mathebe et al, 2004). 
Redox properties of the conducting polymers especially polypyrrole and polyaniline, 
have been extensively studied with much emphasis on their synthesis and 
characterization. Polypyrrole and polyaniline are considered to be the most promising 
polymers for sensor development due to their ease of preparation, stability and good 
conductivity. The chemical structures of conducting polymers together with their facile 
methods of assembly make them compatible with much naturally found chemistry, thus 
promoting their interaction with biological molecules. This therefore has led to the 
application of these polymers in biosensor construction. Biosensors have found great 
application in various fields such as biotechnology, health care, medicine and pollution 
monitoring (Malhotra et al, 2006).   
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In this study the conducting polymer poly (8- anilino-1-napthalene sulfonic acid) was 
used in the construction of a drug metabolism biosensor where it functioned by 
transporting electrons between the electrode and the active centre of the enzyme. The 
main objective of the study was to demonstrate electrochemical reactivities of SSRIs 
when in contact with the enzyme CYP2D6. The responses obtained from these studies are 
clearly discussed in chapter four. 
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3. EXPERIMENTAL: 
3.1 Reagents: 
Cytochrome P450-2D6 Isozyme (CYP 2D6) also known as debrisoquine hydroxylase; 
EC 1.14.14.1 was obtained from Sigma as a purified 200 units/mg enzyme that did not 
contain CYP dehydrogenase and other proteins. One unit of CYP2D6 is the amount 
required to convert 1 nanomole of bufuralol to hydroxybuforol per minute at pH 7.4 at 
370C. Other reagents used were 8-anilino-1-napthalene sulfonic acid, ammonium hydrate 
salt 97% (ANSA), Sulfuric acid which are all products of Fluka. 0.1 M phosphate buffer 
(0.1 M KCl pH 7.4) (PBS) was prepared from Sigma-Aldrich’s anhydrous disodium 
hydrogenorthophosphate, dihydrogenorthophosphate dihydrate and potassium chloride. 
The drugs used for analyses are; namely sertraline, fluoxetine, fluvoxamine, paroxetine, 
zimelidine, clomipramine as well as the known CYP2D6 substrate, debrisoquine sulphate 
were all supplied by Sigma-Aldrich’s and were used as received dissolved in PBS. 
Analytical grade argon used to degas the cell solutions was obtained from Afrox, SA. 
When not used solutions were kept refrigerated at 50C. 
 
3.2 Electrochemical setup: 
Electrochemical experiments were carried out with a BAS 100 W electrochemical 
workstation from BioAnalytical Systems (BAS, West Lafayette, IN) operated in the 
cyclic square wave and differential pulse voltammetric modes or constant potential 
amperometry. A 20 mL electrochemical cell was used in a three electrode configuration 
consisting of a 0.0177 cm2 gold disk working electrode (BAS, West Lafayette, IN), Pt 
wire auxiliary electrode and Ag/AgCl reference electrode (with a 3 M NaCl salt bridge). 
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3.3 METHODOLOGY 
3.3.1 Preparation of 8-anilino-1-napthalene suphonic acid on Gold      
                                                 electrode: 
Prior to polymerization of ANSA, the Au disk electrode was polished on aqueous slurries 
of 1μm, 0.3 μM and 0.05 μM alumina and sonicated in distilled and deionised water 
processed with a milli-Q water purification apparatus (Millipore). The polished Au electrode 
was then scanned in a 0.5 M H2SO4 solution from -1200 mV to +1500 mV at 50 mV/s. 
The auxiliary Pt electrode was cleaned by the flaming method and then rinsed with 
deionised water.  
The electropolymerization of ANSA was performed in a cell solution containing 0.01 M 
of the ANSA monomer in 20 mL 0.5 M H2SO4 solution degassed with argon for 15 min. 
The potential was cycled from -300 mV (initial potential, Ei) to +1100 mV (switch 
potential, Eλ), at a potential scan rate of 50 mV/s. An argon blanket was maintained on 
top of the cell solution during the polymerization process which was stopped after 5 
voltammetric cycle.  Poly (8-anilino-1-napthalene sufonic acid) PANSA was conditioned 
for biosensor application by rinsing out superficial acid and un-reacted monomer and 
then incubated in PBS. This electrode will be referred to as Au/PANSA electrode.  
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3.3.2 Characterization of Au/PANSA electrode in 0.5 M H2SO4   using 
                                     Cyclic voltammetry (CV): 
Characterization of the polymer film was carried out in a 20 mL 0.5 M H2SO4 solution 
which was degassed for 15 min. The potential was cycled from a Ei of -200 mV to a Eλ, 
of +1100mV at different scan rates: 5, 10, 15, 20, 30, 40, 60, 80, 100, 150, 200, 250, 300, 
350, 400, 450 and 500 mV/s. During the characterization process, the argon gas was kept 
on top of the solution in order to prevent the interference by oxygen. Calculations for the 
surface concentration of the polymer as well as the electron transfer coefficient were 
estimated from the obtained results. 
 
3.3.3 Characterization of Au/PANSA electrode in (0.1M KCl,pH 7.4) 
                      (PBS) using Cyclic Voltammetry (CV):                                
Characterization of the polymer in PBS was repeated with a freshly prepared Au/PANSA 
electrode but in this case, the characterization was carried out in the presence of 20 mL 
PBS solution which was also degassed for 15 min. The potential was cycled from -300 mV 
(initial potential, E
i
) to +1100 mV (switch potential, E
λ
), at different scab rates: 5, 10, 15, 20, 
30, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450 and 500 mV/s. An argon blanket 
was kept on top of the solution in order to prevent interferences by oxygen. Both the 
surface concentration as well as the electron transfer coefficient was determined from the 
results. 
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3.4 Enzyme immobilization: 
The conditioned Au/PANSA electrode was reduced potentiostatically in 5 mL PBS under 
argon atmosphere by applying a c potential of -500 mV until a steady state current was 
attained in about 10 min. 20 μL (of 200 units/mg) concentration of solution CYP 2D6 
was added to the 5 mL cell solution and the Au/PANSA film was oxidized at +650 mV 
for 15 min during which the polymer was doped with CYP 2D6. The resultant biosensor 
namely; Au/PANSA/CYP2D6 was rinsed in PBS to remove unbound enzyme and stored 
refrigerated at 40C.   
 
3.4.1 Characterization of Au/PANSA/CYP2D6 using CV and SWV:
Characterization of Au/PANSA/CYP2D6 bioelectrode was carried out using CV in the 
presence of 5 ml PBS which was degassed for 15 min. This reaction was achieved by 
cycling the potential from a Ei of -200 mV to a Eλ, of -1100 mV at different scan rates: 5, 
10, 15, 20, 30, 40, 60, 80, 100, 150 and 200 mV/s. During the characterization, an argon 
blanket was kept on top of the solution. 
Another bioelectrode was freshly prepared and used for the characterization of the 
polymer using SWV. To achieve the characterization, 5 mL PBS solution was used which 
was degassed for 15 min. The potential was scanned from a Ei of -500 mV to a Eλ, of -
1100 mV during which an argon blanket was kept over the solution eliminating oxygen. 
SWV experimental conditions were: sensitivity 10 μA/V, SWV amplitude 25 mV Step 
potential 4 mV and at frequencies of 5, 10 and 15 Hz.  
 
 
 
3.5 Electrochemical measurements: 
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In a typical determination, the biosensor (Au/PANSA/CYP2D6), Ag/AgCl reference 
electrode and platinum wire were placed in the test 5 mL PBS solution and connected to 
the BAS 100 W electrochemical workstation. The Au/PANSA/CYP2D6 bioelectrode was 
used to study the reactivities of the following compounds: Fluoxetine, fluvoxamine, 
citalopram, sertraline, zimelidine and debrisoquine sulphate in undegassed PBS. Analyte  
analyses were accomplished with freshly prepared bioelectrodes in oxygenated PBS to 
which aliquots of the respective types of analyte solutions was added to final 
concentrations of 0.2 to 1.6 μM. The PBS solution was stirred after each addition of 
analyte in order to ensure homogeneity of the solutions prior to analyses. The same 
procedure was carried out for the inhibitor paroxetine. 
CV experiments were carried out at a potential window of Ei of +400 mV to a Eλ, -800 
mV, at a potential scan rate of 10 mV/s and at a sensitivity of 10 μA/V.  
The investigation was also carried out with DPV at a potential window of +400 mV to -
700 mV and scan rate of 10 mV/s. DPV experimental conditions were: sensitivity 10 
μA/V, pulse amplitude 50 mV, current sampling width 17 msec and pulse width of 50 
msec.  
The reactivities of the biosensors towards these compounds were also studied using SWV 
at a potential window of +400 mV to -700 mV. SWV experimental conditions were: 
sensitivity 10 μA/V, SWV amplitude 25 mV, SWV frequency 15 Hz and Step potential 4 
mV. 
Calibration curves were plotted for all the test compounds from the DPV responses of the 
biosensor. The Michaelis-Menten region (hyperbolic region) of the biosensor responses 
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at high analyte concentrations were fitted to the electro-enzyme Michaelis-Menten 
kinetics in accordance with the equation:  
 
I = nFAk
cat 
l[CYP2D6] S/(K
m 
+ S) = I
max
S/(K
 َ
m 
+ S) (1)  
 
In Equation (1) I is the observed cathodic peak current, n is the number of electrons; F is 
Faraday constant (96,485 C/mol), while A, k
cat
, and l are the surface area of the electrode 
(0.0177 cm
2
), turnover rate constant and the thickness of the electroactive layer, 
respectively. S is the substrate concentration; K َ
m 
is the apparent Michaelis-Menten 
constant and I
max 
is the maximum current obtainable from the sensor. I
max 
and K 
 َ
m 
values 
of the sensor were evaluated.  
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4. RESULTS AND DISCUSSION: 
4.1 Electrosynthesis of PANSA on gold electrode: 
PANSA was grown on a 0.0071 cm2 disk electrode surface in an acidic medium by 
the potentiodynamic oxidative polymerisation of 0.01 M ANSA in 0.5 M H
2
SO
4 
at 50 
mV/s scanning anodically from – 300 to + 1100 mV/Ag-AgCl. Figure 4.1 shows a 
typical cyclic voltammogram of the polymer film on Au produced after 5 
voltammetric cycles. 
It can be seen that upon polymerization, PANSA possesses one redox couple with a 
polymerisation formal potential, E
0
′, of +425 to +440 mV compared to PANI, which 
has three redox couples as shown by the work of (Iwuoha et al, 1997; Mathebe et al, 
2004). Using the PANI CV as a reference point, the redox couple observed in the 
synthesis of PANSA is attributable to the electrochemistry of p-benzoquinone formed 
in the polymerisation process.  
This behaviour of PANSA was found to be closely related to that observed in a study 
carried out by (Mazeikiene et al, 2006) in which one redox couple was also observed 
when aminonaphthalene sulphonates were polymerized in the presence of 0.1 M 
sulphuric acid. One redox couple was also observed in another study in which PANI 
was polymerized in the presence and absence of sodium dodecyl sulphate (Kanungo 
et al, 2002). These studies are a confirmation that aniline in 8-anilino-1-napthalene 
sulphonic acid can be polymerized. 
The anodic shift in the polymerization of ANSA shows that oxidation of ANSA on 
the polymer involves charge transportation across the polymer film. The 
unsymmetrical shape of the anodic peak indicates oxidation of ANSA coupled to a 
follow-up reaction and other physical processes which in this case are polymerization 
and adsorption. On the other hand the symmetry of the cathodic peak shows that the 
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only event here is the reduction of adsorbed polymer. There is an anodic shift in the 
polymerisation peak potential with the result that the E
0
′ values increased from +425 
mV for the first polymerisation cycle to +440 mV which indicates that oxidation of 
ANSA on already deposited polymer involves charge transportation across the 
polymer film and therefore energetically more demanding, whereas the reduction of 
the accumulated polymer film becomes easier. 
Characterizations of both PANSA and PANI in the presence of their respective 
polymerization acidic media show similar electrochemistry as denoted by the 
configuration of the peaks. Evidence of this can be seen in figure 4.2 where the 
characterization of PANSA shows a similar electrochemistry to that of PANI in the 
work done by (Mathebe et al, 2005; Lindofors et al, 2002). 
The role of the PANSA film in the biosensor construction was to shuttle electrons 
between the Au disk electrode and the active site of the immobilized enzyme and it 
also served as a point of attachment for the enzyme CYP 2D6. 
 
 
 94
 
 
 
 
 Fig. 4.1 Electrosynthesis of PANSA film on a Au electrode in 0.5 M H2SO4 at a potential window  of  
-300 mV  to +1100 mV and scan rate of 50 mV/s  
 
 
 
Fig. 4.2 Electrochemical characterization of the PANSA film in 0.5 M H2SO4 at 5, 40, 80, 150, 250 
and 350 mV/s at a potential window of -300 mV to +1100 mV. 
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4.2 CV characterization of Au/PANSA electrode in 0.5M  H2SO4
The characterization of the PANSA polymer film in acid medium was carried out at 5, 
10, 15, 20, 25, 30, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450 and 500 mV/s in 
which two redox couples were observed. Figure 4.2 illustrates these results but only 
for the scan rates; 5, 40, 80, 150, 250 and 350 mV/s. The chose of these particular 
responses was to provide a clear illustration of the growth of the polymer. As the scan 
rates where increased during the study, there was less stability in the polymer. This is 
due to the fact that the mobility of the polymer reduced and there was difficulty in the 
immobilization of the enzyme. However, there was no effect on the polymer 
thickness.  
Similar voltammograms have been reported for polyaniline (Iwuoha et al, 2006; 
Iwuoha et al, 1997; Lindofors et al, 2002; Mazeikiene et al, 2006) confirming that 
aniline in anilinonapthalene sulfonic acid can be polymerized. The redox couples A/B 
and C/D are attributed to intrinsic redox processes of the polymer. The redox couple 
A/B observed at approximately +350 mV is as a result of the transformation of aniline 
in ANSA from the reduced polyleucoemeraldine state to the partly oxidized 
polyemeraldine state. The redox couple C/D in the region approximately around +600 
mV is due to the transition of polyleucoemeraldine state to the pernigraniline state, 
which is accompanied by oxidation of ANSA monomer. The multiscan 
voltammograms of the PANSA film modified Au electrode in 0.5 M H2SO4 solution 
shown in figure 4.2 indicate that the peak potentials as well as the peak currents were 
seen to vary as the scan rates were varied. This indicated that the polymer was 
electroactive and that electron diffusion was taking place along the polymer chain 
(Brahim et al, 2003). The main peaks of the polymer are illustrated in figure 4.3 and 
are used for further description of the polymer. 
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Figure 4.5 and figure 4.6 show the linear dependency of the current on the scan rate 
for the main redox couple C/D. This is indicative of a thin surface bound conducting 
electro-active polymer film undergoing a rapid reversible electron transfer reaction 
along the polymer backbone possibly through the conjugated benzene ring units 
making up the chain. Ip,c (peak C) / Ip,a (Peak D) which was obtained to be  ~1.1  
indicating that the polymer behaved as a stable redox species adsorbed on the 
electrode surface undergoing reversible electrochemistry. A similar behaviour was 
also observed in the work carried out by (Brahim et al, 2003; Mu te al, 1997).  ∆Ep 
[Ep,a (Peak 2) – Ep,c (Peak 3) ] was calculated for the polymer film grown at different 
scan rates but the film grown at 50 mV/s resulted in a value of ∆Ep lower than 65 mV 
which was also seen from the work of (Brennan et al, 1996; Bistolas et al, 2005). This 
suggested that the polymer grown at this scan rate exhibited a reversible and a fast 
electrochemistry as compared to polymer grown at other scan rates which is 
suggestive of a slow electron transfer rate. 
The surface concentration of the polymer was estimated to be 1.0257 x 10-6 mol cm-2 
(0.6 ± 0.1) using the Brown-Anson method illustrated as follows.  
Ip  = n2 F2 Г* PANSA A υ 
4RT 
Where n represents the number of electrons involved in the reaction, F is the Faraday 
constant (96,584 C/mol), Г*PANSA is the surface concentration of the PANSA film 
(mol cm2), ν is the scan rate (mV/s), A is the electrode area of the electrode (0.0177 
cm2), R is the universal gas constant (8.314J (mol K)-1) and T is the temperature of the 
system (298 K). The magnitude of the peak currents was seen to increase upon 
increment of the scan rate suggesting that the peak currents are diffusion controlled.  
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De is the electron charge transport coefficient sometimes also known as the rate of 
electron charge propagation along the polymer chain. The following equation is the 
Randel-Sevcik method used for the estimation of this coefficient and was found to be 
3.8225 x 10 2 cm s-1. For the accuracy of this calculation, there should be no variation 
in the potential with scan rate. Only the variation in scan rate is essential in this case. 
The increased value obtained in this study as compared to PANI studies in which 
(Mathebe et al, 2004) reported a value of 8.68 x 10-9 cm s-1 and (Iwuoha et al, 1996) 
reported a value of 6.46 x 10-8 cm s-1 (0.6 ± 0.1). This gives an indication of a much 
faster electron charge transfer. 
 
Ip / υ1/2 = 0.4463 (nF )3/2  De Г *PANSA A 
L (RT)1/2
Where L represents the polymer thickness. 
 
 
Fig. 4.3 Electrochemical characterization of the PANSA film in 0.5 M H2SO4 on Au electrode 
illustrating the main polymerization peaks. 
 98
 
 
 
 
4.3 CV characterization of Au/PANSA electrode in 0.1M Phosphate 
buffer (0.1M KCl,pH 7.4) (PBS): 
The characterization of the PANSA film was also carried out in PBS as stipulated in 
section 3.4.2. The study was carried out at   5, 10, 15, 20, 25, 30, 40, 60, 80, 100, 150, 
200, 250, 300, 350, 400, 450 and 500 mV/s but shown in figure 4.4 are the responses 
for 5, 40, 80, 150, 200 and 350 mV/s. The aim of this experiment was to confirm the 
conductivity and immobilization of the polymer. Figure 4.4 illustrates the CV 
characterization of the polymer film in PBS indicating two cathodic peaks in the 
reductive scan while there are no peaks observed in the oxidative scan. The peak 
approximately at -26 mV confirms the attachment of PANI, which was also observed 
in previous PANI studies carried out by (Ngece et al, 2004) at approximately the same 
region. The peak at approximately +360 mV denotes the presence of NSA in PANSA. 
The multiscan voltammograms of the PANSA film modified Au electrode in the PBS 
solution shown in figure 4.4 indicate that the peak potentials as well as the peak 
current varied as the scan rates were varied. This indicated that the polymer was 
electroactive and that electron diffusion was taking place along the polymer chain 
(Iwuoha et al, 1998; Qu et al, 2005). The slight shift in the peaks is indicative of the 
conductivity ( Iwuoha et al, 1997) of the polymer leading to the conclusion that the 
polymer was effective for use in biosensor construction.  
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Fig 4.4 Electrochemical characterization of the PANSA film in PBS at different scan rates: 5, 40, 
80, 150, 200 and 350 mV/s  at a potential window of -300 mV to +1100 mV. 
 
 
 
Fig. 4.5 Dependency of peak current on potential scan rate for the Au/PANSA 
electrode. 
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Fig.4.6 Peak currents as a function of square root of scan rate for the Au/PANSA 
electrode 
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4.4 CV and SWV characterization of Au/PANSA/CYP electrode in 
0.1M 
Phosphate  buffer     (0.1M KCl,pH 7.4)(PBS): 
After enzyme immobilization, it was important to access whether the enzyme was 
stationed on the polymer surface or not. This assessment was achieved using CV at a 
potential window of -300 mV to +1000 mV at scan rates; 5, 10, 15, 20, 30, 40, 60, 80, 
100, 150, 200, 250, 300, 350, 400, 450 and 500 mV/s. Figure 4.7 shows the CV 
voltammogram of the characterization at 5, 15, 30, 60, 100 and 150 mV/s where one 
redox couple was observed. As the scan rates increased, the amplitude of the peaks 
also increased confirming immobilization of the enzyme. On the other hand, a slight 
shift in both the current and the potential was observed illustrating that the polymer 
had not lost its conductivity and electro-activity upon enzyme immobilization 
(Iwuoha et al, 1998; Qu et al, 2005).  
Characterization with SWV was achieved at the potential window of -500 mV to 
+900 mV carried out at different frequencies; 5, 10 and 15 Hz. The SWV 
voltammogram  illustrated in figure 4.8 shows two peaks observed on the reductive 
scan; one in the region around +250 mV and the other in the region around -350 mV. 
The same behaviour observed for the bioelectrode in CV was also observed in SWV. 
Upon repeated scans the amplitude of the peaks was seen to increase confirming the 
immobility of the enzyme on the polymer surface. Conductivity and electroactivity 
were also confirmed by the slight shift observed for both the current and the potential 
also indicating fast charge transportation along the polymer chain. (Iwuoha et al, 
1998; Qu et al, 2005). The D
e 
value of 3.788 x 102 cm s-1obtained in this study gives 
evidence of a more conductive polymer when compared values reported by (Iwuoha et al, 
2004). The surface concentration was also determined and estimated to be 6.684 x 10-6 
mol cm-2 illustrating an increased value to that reported for the polymer in the absence 
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of the enzyme.  It should be noted that both of these calculation were achieved as a 
result of CV responses and not SWV responses. 
 
 
Fig. 4.7 Electrochemical characterization of the Au/PANSA/CYP in PBS at 5, 15, 30, 60, 100 and 
150 mV/s at a potential window of  -300 mV  to +1100 mV. 
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Fig. 4.8 Electrochemical characterization of the Au/PANSA/CYP in PBS at 5, 10 and 15 Hz at a 
potential window of -500 mV to +800 mV. 
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4.5 PANSA-mediated electrocatalytic reduction of substrates and 
SSRI drugs: 
CYP2D6 is known to have the ability to metabolise debrisoquine sulfate, a known 
substrate of this enzyme (Cerqueira et al, 2000). In this work this compound was 
metabolized by a CYP2D6 biosensor. The responses obtained from this study were 
compared to those obtained when the same biosensor was used in the 
biotransformation of SSRIs and a tricyclic antidepressant. All the biosensor responses 
obtained for the substrate, the SSRIs and the tricyclic antidepressants were very 
similar and the conclusion that the SSRIs were substrates of CYP2D6 was finally 
made. In the sections below the CV, DPV and SWV result of these compounds 
namely; fluoxetine, fluvoxamine, zimelidine, clomipramine, sertraline,   paroxetine 
and debrisoquine sulphate, are discussed.  
A number of calculations have been made based on the data that was obtained. 
Among these was the determination of Km and Imax in the linear range of the 
individual biosensor systems. These values were obtained by plotting calibration 
curves, which are plots of the current against analyte concentrations which in our case 
are the concentrations of the above mentioned compounds.. The importance of 
plotting the calibration curves was to also determine the sensitivity and detection 
limits of the respective biosensors as shown in table 4.1. The sensitivities of the 
biosensors were determined as the slopes of the calibration curves. The sensors are 
more sensitive as a result of the electrochemical immobilization of CYP2D6 as well 
as the presence of the electron mediator; PANSA (Svobodova et al, 2002).  
The detection limit was also determined and the importance of doing so is to know 
what the lowest concentration a particular biosensor can detect, lower than the least 
amount of concentration which that particular biosensor was subjected too. Detection 
limits are dependant on the background current exhibited by the polymeric film. The 
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current is a function of the morphology of the polymer which depends on the 
polymerization conditions employed (Grennan et al, 2006). These values are also 
stipulated in table 4.1 were a clear comparison among the sensor systems can be 
made.  
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4.5.1 Electrocatalytic reduction of SSRIs using CV: 
Of great interest to our study was the similarity observed in the electrochemistry of 
fluoxetine (figure 4.9) and sertraline (figure 4.10). These figures illustrate the 
voltammetric responses of the Au/PANSA/CYP2D6 biosensors in the absence and 
presence of fluoxetine and sertraline using CV under aerobic conditions in the 
presence of PBS. The voltammograms show that as the potential was scanned 
reductively from +500 mV to –800 mV, in which the reduction (cathodic) current 
steadily increased to a maximum value after which the current decreased until, the 
switch potential was reached. It should be noted that illustrated in the figures are the 
potential windows from +500 mV to –700 mV. Scanning oxidatively (anodically) did 
not show any anodic peak.  
One prominent peak was observed in the cathodic scan when the analyte 
concentration was increased steadily from 0.2 μM to 1.2 μM.  The first reductive 
cyclic voltammogram illustrated from the top shows that the solution contains 1.2 μM 
fluoxetine and 1.2 µM sertraline respectively. This defined cathodic peak depicts the 
coupling of a fast electron transfer reaction taking place at the electrode surface to a 
fast chemical process in which the reduced electro-active species have been used up.  
During the cathodic scanning Fe2+ was produced as a result of the binding of the 
analytes to the active sites of CYP2D6 which was then used up in a fast follow-up 
chemical reaction, thus making it unavailable for re-oxidation during the anodic scan, 
which is why there is no peak in the anodic scan. The irreversible cyclic 
voltammograms recorded in aerobic conditions suggests that there is a binding of 
molecular oxygen to the Fe2+ heam redox centre of the enzyme (Iwuoha et al, 2004). 
As mentioned in chapter two, this process involves a second electron which is 
responsible for the cleavage of the di-oxygen bond leading towards the generation of 
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products (Shumyanteva et al, 2005). In the case of the biotransformation of fluoxetine 
by the Au/PANSA/CYP2D6 biosensor, the product generated is norfluoxetine. This 
metabolite was produced as a result of the abstraction of the methyl group from 
fluoxetine resulting in a water soluble and easy excretable compound (Heimke et al, 
2000, Iwuoha et al, 1998). The same biotransformation reaction was assumed for the 
Au/PANSA/CYP2D6 biosensor towards sertraline in which desmethylsertraline was 
the resultant product also produced by the abstraction of methyl from sertraline. 
The peak observed below that observed for 1.2 µM, illustrates the presence of the 1.6 
μM concentrations for both sertraline and fluoxetine respectively, in which a decrease 
in the current was observed indicating a case of substrate-inhibition. This therefore 
suggests that beyond the addition of 1.2 µM for both fluoxetine and sertraline the 
activity of CYP2D6 had been altered due to the unavailability of the enzyme’s active 
site for further binding of the analytes (Conn et al, 1987). This agrees with what has 
been reported by other researchers on their work on CYP2D6 (Iwuoha et al, 2004; 
von Moltke et al, 1997; Margolis et al, 2000). This is therefore confirmation that 
fluoxetine and sertraline are both substrate – inhibitors of CYP2D6. Therefore upon 
continuous cycling, the current continues to reduce.  
The Au/PANSA/CYP2D6 biosensor responses in the absence and presence of 
clomipramine, fluvoxamine, debrisoquine sulphate and zimelidine are illustrated in 
figures 4.11, 4.12, 4.13 and 4.14 respectively. All the calculations involving these two 
compounds are also illustrated in table 4.1. 
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Fig. 4.9 CV of CYP2D6 biosensor in the presence of varying concentrations of fluoxetine under 
aerobic conditions in the potential window of +500 mV to –700 mV at a scan rate of 10 mV/s 
 
 
Fig. 4.10 CV of CYP2D6 biosensor in the presence of varying concentrations of sertraline under 
aerobic conditions in the potential window of +500 mV to –800 mV at a scan rate of 10 mV/s 
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The Au/PANSA/CYP2D6 biosensor responses in the absence and presence of 
fluvoxamine, zimelidine, clomipramine and debrisoquine sulphate were also studied 
using CV. Although the concentration range studied for the biosensor responses was 
from 0.2 to 1.6 μM, only the responses for 0.2 and 0.4 μM are shown. The 
voltammograms in each case show that as the potential was scanned from +500 mV to 
–800 mV the cathodic current steadily increased to a maximum value after which it 
decreased until, the switch potential was reached. This behaviour was observed for all 
the above mentioned compounds. During the cathodic scanning the heme redox 
centre; Fe2+ was produced from the interaction of the respective analytes with the 
heme redox cenre; Fe3+ and later used up in a fast follow-up chemical reaction, thus 
making it unavailable for re-oxidation during the anodic scan. This is said to be a 
change from the low spin form of the enzyme to the high spin form which has a high 
affinity for oxygen. The irreversible cyclic voltammograms recorded for each analyte 
in aerobic conditions suggests that there is a binding of oxygen to the Fe2+ heam 
redox centre of the enzyme (Wilson et al, 2004).  For all of these compounds one 
prominent peak was observed in the cathodic scan when the analyte concentration was 
increased steadily from 0.2 μM to 1.6 μM. A cathodic peak in the region around -300 
mV was observed for fluvoxamine and in the region around – 400 mV a cathodic 
peak was also observed for zimelidine. For clomipramine and debrisoquine sulphate, 
the peaks were observed for both compounds in the region approximately +450 mV. 
As mentioned before, it is the second electron which assists in the release of products 
even though the products do not necessary follow the same reaction pathway. 
Debrisoquine sulphate is hydroxylated to 4-hydroxydebrisoquine by the 
Au/PANSA/CYP2D6 biosensor to produce an excretable compound while 
 110
 
 
 
 
clomipramine is demethylated to desmethylclomipramine. These findings are all as a 
result of their respective interaction with CYP2D6 (Heimke et al, 2000). 
It was also found that the biotransformation of zimelidine and fluvoxamine 
respectively by the Au/PANSA/CYP2D6 biosensor also produced water soluble 
compounds. In the case of zimelidine, desmethylzimelidine was produced as a result 
of the abstraction of methyl while in the case of fluvoxamine, an o-demethylated 
metabolite was produced. This metabolite was also produced as a result of the 
abstraction of methyl but at the very same time, an oxygen atom from the surrounding 
reaction solution was added, producing it into a carboxylic acid (Heimke et al, 2000). 
Finally, from the voltammograms it is evident that the biosensor responses obtained 
for the analytes are closely related to that of the biosensor responses of the known 
substrate of CYP2D6, namely debrisoquine sulphate. This therefore suggests that 
these analytes /SSRIs and the tricyclic antidepressants: clomipramine are substrates of 
CYP2D6. This is deduced from the fact that the cathodic peaks observed for all these 
biosensors occur at very similar potentials. To further substantiate these findings, 
DPV and SWV analyses were also carried out. 
The calibration curve of fluoxetine is shown in figures 4.15 where it follows 
Michaelis-Menten kinetics in which Km and Imax were determined and their values are 
shown in table 4.1. Figure 4.15 also shows the linear range of the fluoxetine biosensor 
in which was established in the region from 0 to 1.0 µM (with r = 0.968). All 
calculations for the biosensor are all stipulated in table 4.1. Calibration curves for 
zimelidine and fluvoxamine are shown in figure 4.16 and 17 respectively. A linear 
relationship in the case of zimelidine was observed in the range from 0 to 1.4 µM 
(with r = 0.981) were Km, Imax, sensitivity and the detection limit of the biosensor 
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were estimated. The linear range for fluvoxamine was established in the region from 0 
to 1.0 µM (with r = 0.919) where the same calculations were determined.  
 
Fig. 4.11 CV of CYP2D6 biosensor in the presence of varying concentrations of clomipramine under 
aerobic conditions in the potential window of +500mV to –700 mV at a scan rate of 10 mV/s 
 
 
 
Fig. 4.12 CV of CYP2D6 biosensor in the presence of varying concentrations of fluvoxamine under 
aerobic conditions in the potential window of +500mV to –700 mV at a scan rate of 10 mV/s 
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Fig. 4.13 CV of CYP2D6 biosensor in the presence of varying concentrations of debrisoquine 
sulphate under aerobic conditions in the potential window of +500mV to –700 mV at a scan rate of 
10 mV/s 
 
Fig. 4.14 CV of CYP2D6 biosensor in the presence of varying concentrations of zimelidine under 
aerobic conditions in the potential window of + 500 mV to –800 mV at a scan rate of 10 mV/s 
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Fig 4.15 Calibration curve of fluoxetine biosensor illustrating the 
 linear range of the biosensor with a detection limit of 0.9  µM and r ² = 0.968 
 
Fig. 4.16 Calibration curve for zimelidine biosensor with 
 a sensitivity of  3.220 x10-1 and a detection limit of  0.03  µM 
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Fig. 4.17 Calibration curve of fluvoxamine biosensor with 
a sensitivity of 9.470 x 10-1  and a detection limit of 0.15 µM  . 
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4.5.2 Electrocatalytic reduction of SSRIs using DPV: 
DPV was also carried out to study the reactivities of the Au/PANSA/CYP biosensor 
towards the biotransformation of SSRI. The biosensor responses in the absence and 
presence of these analytes can be illustrated in figure 4.18 for zimelidine, figure 4.19 
for clomipramine, figure 4.20 for debrisoquine sulphate, figure 4.21 for fluvoxamine, 
figure 4.22 for sertraline and figure 4.23 for fluoxetine;  all carried out in aerobic 
conditions. The DPV was performed in a reductive mode by scanning the potential 
from +400 mV to –700 mV however for visual purposes; the figures either show the 
potential window from +200 mV to –500 mV, +300 mV to –500 mV or from +200 
mV to –600 mV. The cathodic current steadily increased to a maximum value after 
which the current was seen as decreasing. One prominent DPV peak was observed in 
the cathodic scan when the concentration of each of the analytes was respectively 
increased steadily from a concentration of 0.2 μM to 1.6 μM. However in some of the 
figures below, this concentration range is not shown in full but shown either from 0.2 
μM to 1 μM or from 0.2 μM to 0.8 μM.  For zimelidine the cathodic peak was 
observed in the region approximately +250 mV, for clomipramine the cathodic peak 
was observed in the region approximately around +270 mV, for fluvoxamine the 
cathodic peak was observed in the region approximately around +200 mV, for 
debrisoquine sulfate this peak was observed in the region approximately around +290 
mV and finally for sertraline and fluoxetine the peak was observed in the region 
approximately around +250 mV. 
After each addition of the respective analytes, an increase in current was observed 
which was also accompanied by a slight shift in potential implying a reduction in the 
redox potential. Presumably, the cathodic biosensor responses, illustrated as the 
cathodic peaks; are due to the coupling of the Fe3+ ↔ Fe2+ electron transfer reaction as 
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well as the electro-catalytic reactions involved in the binding of oxygen to Fe2+ 
(Shumyanteva et al, 2005). According to (Iwuoha et al, 2004), this electro-catalytic 
reaction is fast; however in our case this reaction was achieved at 10 mV/s. As 
mentioned before, this study also produced the water soluble metabolites as discussed 
previously as a result of the mono-oxygenation reaction in which the di-oxygen bond 
is broken by the second electron as shown in scheme 2.2. In this section we can again 
observe the similarity in the electrochemical behaviour of the analytes as compared to 
that of debrisoquine sulphate. The DPV studies have also confirmed the similarities 
which exist between the electrochemistry of sertraline and fluoxetine as shown by 
figures 4.22 and 4.23 respectively. It should also be noted that although the DPV 
studies were carried out in the potential window from +400 mV to -700 mV, shown in 
the figures is the potential window from -100 mV to -400 mV. For both the sertraline 
and fluoxetine studies, an increase in the current was observed upon the addition of 
the respective analytes between the concentration ranges of 0.2 µM to 1 µM. Beyond 
this range, the current decreased illustrating a case of analyte/SSRI inhibition which 
was also observed by the work done by (Iwuoha et al, 2004; von Moltke et al, 1997; 
Margolis et al, 2000). CYP2D6 demethylated these compounds to desertraline and 
nor-fluoxetine. It could therefore be concluded that both of these SSRIs are substrate-
inhibitors of CYP2D6. Another finding of this study was the similarity in the 
electrochemistry of debrisoquine sulphate to that of the SSRIs and the tricyclic 
antidepressant; clomipramine. The experiment with debrisoquine sulphate was carried 
out in order to demonstrate that the CYP2D6 biosensor actually works which was 
proved to be true. This is based on the almost common cathodic peak potential 
observed for the electrochemistry of the known CYP2D6 substrate relative to those 
obtained for the SSRIs and clomipramine. From this we could then deduce that the 
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SSRIs as well as clomipramine are substrates of CYP2D6 due to the presumption that 
the reactivity of the Au/PANSA/CYP2D6 bioelectrode towards debrisoquine sulphate 
is the same as them. As shown in scheme 2.2, the metabolisms of the analytes are 
essentially oxygenation reactions, where the first electron is used to reduce the ferri 
heme of CYP2D6 to the ferro heme. 
The calibration curves for the other SSRIs are shown in the other sections, but in this 
section only the calibration curve for debrisoquine sulphate is shown in figure 4.24 
where the sensitivity, detection limit, Km and Imax were estimated. Their values are 
clearly stipulated in table 4.1.  
 
 
 
Fig. 4.18 DPV of CYP2D6 biosensor in the presence of varying concentrations of zimelidine under 
aerobic conditions in the potential window of +300 mV to –500 mV at a scan rate of 10 mV/s 
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Fig. 4.19 DPV of CYP2D6 biosensor in the presence of varying concentrations of clomipramine 
under aerobic conditions in the potential window of +200 mV to –600 mV at a scan rate of 10 mV/s 
 
 
Fig. 4.20 DPV of CYP2D6 biosensor in the presence of varying concentrations of debrisoquine 
sulphate under aerobic conditions in the potential window of +200 mV to –600 mV at a scan rate of 
10 mV/s 
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Fig.4.21 DPV of CYP2D6 biosensor in the presence of varying concentrations of fluvoxamine under 
aerobic conditions in the potential window of +200 mV to –600 mV at a scan rate of 10 mV/s 
 
Fig.4.22 DPV of CYP2D6 biosensor in the presence of varying concentrations of sertraline under 
aerobic conditions in the potential window of -100 mV to –400 mV at a scan rate of 10 mV/s 
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Fig.4.23 DPV of CYP2D6 biosensor in the presence of varying concentrations of fluoxetine under 
aerobic conditions in the potential window of -100 mV to –400 mV at a scan rate of 10 mV/s 
 
 
Fig. 4.24 Calibration curve of debrisoquine sulphate biosensor  
with a sensitivity of  3.904 x 10-1 and detection limit of 0.02 µM . 
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4.5.3 Electrocatalytic reduction of SSRIs using SWV: 
The reactivities of the Au/PANSA/CYP2D6 biosensor towards the analytes/SSRIs 
were further studied using SWV in the absence and presence of the respective 
analytes. The use of this technique also provided confirmation for the electrochemical 
similarity existing between fluoxetine and sertraline respectively shown as figures 
4.25 and 4.26. Also shown are the SWV responses for fluvoxamine zimelidine 
debrisoquine sulphate and clomipramine illustrated respectively in figure 4.27, 4.28 
4.29 and 4.30, in the absence and presence of these compounds under aerobic 
conditions. The voltammograms show that as the potential was scanned from +500 
mV to –700 mV, the current steadily increased to a maximum value after which the 
current decreased. Illustrated in the provided figures are the potential windows from 
+100 mV to -600 mV, 0 to -600 mV or 0 to -500 mV. 
For sertraline one prominent peak in the region approximately around -200 mV was 
observed in the cathodic scan when the analyte concentration was increased steadily 
from 0.2 μM to 1.2 μM where the current was seen to increase after each addition. In 
vitro and in vivo depression studies by (Kobayashi et al, 1999) indicate sertraline to 
be a possible inhibitor of CYP2D6. Addition of sertraline beyond 1.2 μM, showed a 
decrease in the peak currents suggesting saturation of the enzyme or possibly 
inhibition of the enzyme (Mandrioli et al, 2006). (Mandrioli et al, 2006, Heimke et al, 
2000) suggested sertraline to be an inhibitor of CYP2D6 functioning by binding to the 
substrate binding sites of CYP2D6. Our study has proven otherwise, where at very 
low concentrations of sertraline reductive catalysis was observed and saturation or 
inhibition occurring at high concentrations.   A similar behaviour to that of sertraline 
was also observed for fluoxetine where an increase in the current was observed when 
the analyte concentration was increased steadily from 0.2 μM to 1.0 μM. A prominent 
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peak in the region approximately around +200 mV was observed in the cathodic peak 
during the addition of fluoxetine. Fluoxetine addition beyond this concentration range 
resulted in a decrease in the current also illustrating a case of substrate-inhibition 
(Iwuoha et al, 2004; von Moltke et al, 1997; Margolis et al, 2000). 
One prominent peak was observed in the region approximately around -300mV for 
fluvoxamine, in the region approximately around -305 mV for debrisoqine sulphate 
and in the region approximately around -315 mV for clomipramine.  This was 
observed in the cathodic scans when the analyte concentrations were increased 
steadily from 0.2 μM to 1.6 μM respectively for these compounds. The peaks 
observed for the respective biosensors towards the analytes are a result of the 
transformation of Fe3+ to Fe2+ (Shumyanteva et al, 2005) when the analytes react with 
the active site of the enzyme in the Fe3+ state. The produced high spin state of the 
enzyme was then able to bind molecular oxygen. Again, these biotransformations 
have led to the production of water soluble and easy excretable metabolites (Iwuoha 
et al, 1998) as stated previously. The resultant products were successfully produced 
when the second electron breaks the di-oxygen bond. 
Finally with the SWV results we could confidently say that indeed the SSRIs 
including the tricyclic antidepressant used in our study are substrates of CYP2D6 as 
confirmed by the similarities of the electrochemical behaviour of them relative to that 
of debrisoquine sulphate as observed by the location of their cathodic peaks.  
Figure 4.31 illustrates the calibration curve of sertraline which followed Michaelis-
Menten kinetics. The linear relationship was obtained in the range from 0 to 1.2 μM 
(with r = 0.985). The calibration curve of clomipramine is shown in figure 4.32 (with 
r = 0.980). Km , Imax  , sensitivities and the detection limits were estimated and are 
stipulated in table 4.1.  
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Fig. 4.25 SWV of CYP2D6 biosensor in the presence of varying concentrations of fluoxetine under 
aerobic at a potential window of +100 mV to –600 mV at a frequency of 10 Hz 
 
 
Fig. 4.26 SWV of CYP2D6 biosensor in the presence of varying concentrations of sertraline under 
aerobic conditions at a potential window of +100 mV to –600 mV at a frequency of 10 Hz 
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Fig. 4.27 SWV of CYP2D6 biosensor in the presence of varying concentrations of fluvoxamine 
under aerobic conditions at a potential window of  +100 mV to –600 mV at a frequency of 10 Hz 
 
 
Fig. 4.28 SWV of CYP2D6 biosensor in the presence of varying concentrations of zimelidine under 
aerobic conditions at a potential window of 0 mV to –600 mV at a frequency of 10 Hz 
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Fig. 4.29 SWV of CYP2D6 biosensor in the presence of varying concentrations of debrisoquine 
sulphate under aerobic conditions at a potential window of +100 mV to –600 mV at a frequency of 
10 Hz 
 
Fig. 4.30 SWV of CYP2D6 biosensor in the presence of varying concentrations of clomipramine  
under aerobic conditions at a potential window of 0 mV to –500 mV at a frequency of 10 Hz 
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Fig 4.31 Calibration curve of sertraline biosensor illustrating the 
 linear range of the biosensor with a detection limit of 0.13 µM and r2 = 0.985  
 
 
Fig 4.32 Calibration curve of clomipraminee biosensor illustrating the 
 linear range of the biosensor with a detection limit of 0.05 µM. 
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4.6 Inhibition of CYP2D6 by Paroxetine: 
The DPV of paroxetine was performed in a reductive mode by scanning the potential 
from +400 mV to –700 mV (shown is the potential window from +300 mV to -700 
mV) during which the cathodic current steadily increased to a maximum value after 
which it then decreased. Figure 4.33 shows the DPV voltammetric responses of 
CYP2D6 to PBS in the absence and presence of paroxetine. From the voltammogram 
we can see that after the first addition of paroxetine, there was a decrease in the 
current illustrating enzyme inhibition. This behaviour of the biosensor confirms that 
our biosensor contains CYP2D6.The same behaviour was observed when the 
biosensor responses were studied using SWV (figure 4.34) and CV (figure 4.35). 
Upon subsequent additions, the current continued to decrease accompanied by a slight 
shift in the potential after each addition. This is a case of uncompetitive inhibition in 
which the inhibitor paroxetine has changed the shape of the enzyme. The active site of 
the enzyme has also changed in such a way that the substrate can no longer bind 
(Fersht et al, 1984; Conn et al, 1987). This interaction can be clearly observed in 
figure 4.36 where both fluvoxamine; a known substrate of CYP2D6 was reacted with 
paroxetine in the same cell solution. Figure 4.36 (a) shows an increase in the current 
upon the addition of the substrate but immediately when the inhibitor is introduced 
into the system, the current started to decay. When the inhibitor was first introduced 
into the reaction solution, as shown in figure 4.36 (b); a particular current was 
observed which was seen to decrease upon the addition of the substrate; fluvoxamine. 
The reason for this is the fact that upon the addition of paroxetine, the activity of the 
enzyme is immediately eliminated due to the possible formation of covalent bonds 
between the inhibitor and the active site of the enzyme, observed as the immediate 
decrease in current. From figure 4.36 (b) we can see that even increasing the 
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concentration of the substrate fluvoxamine does not overcome the inhibition (Conn et 
al, 1987; Subehan et al, 2006). 
Inhibition does not mean that biotransformation of paroxetine by CYP2D6 did not 
occur. The product of this reaction was an unstable catechol intermediate which was 
as a result of the oxidative cleavage of paroxetine by CYP2D6. This intermediate is in 
most cases further methylated in the meta-position to the meta-methoxyderivative or 
in the para-position to the para-methoxyderivative (Heimke et al, 2000). 
 
 
Fig. 4.33 DPV of CYP2D6 biosensor in the presence of varying concentrations of paroxetine under 
aerobic at a potential window of +300 mV to –700 mV at a scan rate of 10mV/s. 
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Fig. 4.34 SWV of CYP2D6 biosensor in the presence of varying concentrations of paroxetine under 
aerobic conditions at a potential window of +100 mV to –600 mV at a scan rate of 10mV/s. 
 
Fig. 4.35 CV of CYP2D6 biosensor in the presence of varying concentrations of paroxetine  under 
aerobic conditions at a potential window of + 500 mV to –700 mV at a scan rate of 10 mV/s 
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Fig. 4.36 (a)CV of CYP2D6 biosensor in the presence of varying concentrations of paroxetine and 
fluvoxamine  under aerobic conditions at a potential window of + 100 mV to –700 mV at a scan rate 
of 10 mV/s 
 
Fig. 4.36 (b) DPV of CYP2D6 biosensor in the presence of varying concentrations of paroxetine and 
fluvoxamine  under aerobic conditions at a potential window of + 100 mV to –700 mV at a scan rate 
of 10 mV/s 
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Fig 4.37 Calibration curve of paroxetine biosensor  
with a sensitivity of  -6.964 x 10-1  and a detection limit of -0.085 µM . 
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4.7 Steady State Amperometry: 
The biosensor response time was evaluated from steady state amperometry 
experiments performed at -315 mV. In the experiment, the Au/PANSA/CYP2D6 
biosensor was used as the working electrode in an air saturated PBS cell solution 
which was stirred at 500 rpm. Response time can be described as the time necessary 
to reach 95% of the steady-state current level. The biosensor was polarised at -315 
mV and the background (capacitive) current was allowed to decay to a constant value 
which occurred after about 107 s. Observed from the amperometry results was an 
increase in the current when the respective analytes were added until steady-state was 
reached after some time (Svobodova et al, 2002). We can see that the response times 
are in the order of seconds varying from 20 to 25 s showing that the sensor responses 
can be achieved in real time even if the time required for the background current to 
decay is included. This time is much shorter when compared to the hours required for 
immunoassay. These responses are quite similar to response time values carried out 
by the work of (Iwuoha et al, 2002) were values ~20 s were obtained in the case of 
experiments carried out with modified electrodes, which is the same method 
employed in this particular study. Table 4.1 illustrates the response times of the 
different drug materials. The response times of a few analyses drugs are illustrated in 
figure 4.38 for fluoxetine and fluvoxamine and figure 4.39 for sertraline and 
debrisoquibe sulphate.  
From the results stipulated in table 4.1 we can see that there is a variation in the 
detection limits for the respective biosensors. The detection limits of fluvoxamine, 
sertraline and clomipramine are higher than those observed for the other sensor 
systems. For the other biosensors this is probably as a result of the less homogenous 
distribution of the enzyme molecules on the sensor surface, thus restricting access of 
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the analytes to the active site of CYP2D6 (Svobodova et al, 2002). This is especially 
true for the fluoxetine biosensor whose intra-hepatic concentration is reported in the 
range from 2 to 7 µmol /L (Iwuoha et al, 2004). The detection limit of the two SSRIs 
and the tricyclic antidepressant are in the same concentration range which gives us the 
confirmation that these compounds are substrates of CYP2D6. 
 
 
 
Fig.4.38 Response times of fluvoxamine and fluoxetine. 
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Fig.4.39 Response times of sertraline and debrisoquine sulphate. 
 
Table 4.1: Compounds and their respective biosensor analyses: 
COMPOUND Imax Km Detection 
Limit 
Sensitivity Response 
Times 
FLUOXETINE 9.103x10-7 A 0.9 µM 0.94 µM 6.327x10-1  20 s 
FLUVOXAMINE 1.55x10-7 A 0.79 µM 0.15 µM 9.470x10-1  22 s 
ZIMELIDINE 5.123x10-7 A 0.81 µM 0.03 µM 3.220x10-1  21 s 
SERTRALINE 6.011x10-7 A 0.75 µM 0.13 µM 3.021x10-1  25 s 
CLOMIPRAMINE 5.121x10-7 A 0.82 µM 0.05 µM 3.398x10-1  19 s 
DEBRISOQUINE 
SULFATE 
1.121x10-7 A 0.81 µM 0.02 µM 3.904x10-1  23 s 
PAROXETINE 1.100x10-8 A 0.5 µM -0.085  µM -6.964x10-1  20 s 
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4.8 Conclusion: 
PANSA-on-gold electrode modified with CYP2D6 is suitable for application in drug 
biotransformation biosensors as observed from the output of this study. PANSA 
served as a point of attachment for the enzyme as well as an efficient electron 
mediator between the redox centre of CYP2D6 and the electrode surface. The results 
obtained are confirmation that the Au/PANSA/CYP2D6 biosensors were successful in 
the reductive catalysis of the various SSRIs into respective water soluble and easy 
excretable metabolites. The catalytic current responses were amperometrically 
monitored by cyclic, differential pulse and square wave voltammetric techniques 
where an increase in current was observed for the substrates and the reverse for the 
inhibitor. Another interesting aspect of this work is the similarity existing between the 
electrochemistry of debrisoquine sulfate and that of the used SSRIs resulting in a 
conclusion that the SSRIs are CYP2D6 substrates. Prior studies of sertraline have 
indicted sertraline to be a possible inhibitor of CYP2D6, our study has indicated that 
at very low sertraline concentration, this compound behaves as a substrate of 
CYP2D6 as illustrated by an increase in current upon addition of sertraline aliquots up 
to the saturation/inhibition cross-over concentration determined by the amount of 
CYP2D6 in the biosensor. This behaviour of sertraline was found to be very similar to 
that observed for fluoxetine. On the other hand, the inhibitory effects of paroxetine 
were also explored and an irreversible inhibition was observed since there was no 
current change even in the presence of a substrate. From the calibration curves, linear 
responses were established in which the sensitivities as well as the detection limits 
were estimated. Michaelis-Menten kinetics was used to determine the values of Km 
and Imax of the various biosensor systems. The apparent Michaelis-Menten constants 
were found to be higher than the peak plasma concentration (Cmax) value of 0.55 
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μM, thereby making the sensor systems suitable for the determination of the 
respective analytes in serum. 
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